pmid,title,authors,journal,pub_date,doi,abstract,article_type
41499749,Motor Vehicle Crash Prevention. Reply.,"Klauer Sheila G, Doerzaph Zachary R",The New England journal of medicine,2026 01,10.1056/NEJMc2513175,,Correspondence
41499748,Motor Vehicle Crash Prevention.,Bartzak Patricia J,The New England journal of medicine,2026 01,10.1056/NEJMc2513175,,Correspondence
41499747,Motor Vehicle Crash Prevention.,Czaharyn Anthony G,The New England journal of medicine,2026 01,10.1056/NEJMc2513175,,Correspondence
41499746,Motor Vehicle Crash Prevention.,"Philip Pierre, Tamisier Renaud, McNicholas Walter T",The New England journal of medicine,2026 01,10.1056/NEJMc2513175,,Correspondence
41499745,Motor Vehicle Crash Prevention.,Shah Viral N,The New England journal of medicine,2026 01,10.1056/NEJMc2513175,,Correspondence
41499744,Azithromycin for Infants in Mali to Reduce Mortality. Reply.,"Haidara Fadima Cheick, Adubra Laura, Ashorn Per",The New England journal of medicine,2026 01,10.1056/NEJMc2516391,,Correspondence
41499743,Azithromycin for Infants in Mali to Reduce Mortality.,"Chen Feng, Huang Xiu-Feng, Chu Maoping",The New England journal of medicine,2026 01,10.1056/NEJMc2516391,,Correspondence
41499742,Azithromycin for Infants in Mali to Reduce Mortality.,"Pei Junjuan, Chen Xinying",The New England journal of medicine,2026 01,10.1056/NEJMc2516391,,Correspondence
41499741,Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis. Reply.,"Maitland Kathryn, Petrucci Roberta, Thomson Johanna",The New England journal of medicine,2026 01,10.1056/NEJMc2515876,,Correspondence
41499740,Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis.,"Han Xiang-Yu, Qi Hui-Ru",The New England journal of medicine,2026 01,10.1056/NEJMc2515876,,Correspondence
41499739,Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis.,"Pan Hui, Zheng Xiaoling, Zhang Yulong",The New England journal of medicine,2026 01,10.1056/NEJMc2515876,,Correspondence
41499738,Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis.,"Heyman Samuel N, Marcus Esther-Lee, Brezis Mayer",The New England journal of medicine,2026 01,10.1056/NEJMc2515876,,Correspondence
41499737,Serogroup Switching in Neisseria meningitidis with Dual Antibiotic Resistance.,"Howie Rebecca L, Sharma Shalabh, Kyle Jennifer L, Rubis Amy B",The New England journal of medicine,2026 01,10.1056/NEJMc2507652,,Correspondence
41499733,Functional Dyspepsia.,"Pasricha Pankaj J, Talley Nicholas J",The New England journal of medicine,2026 01,10.1056/NEJMcp2501860,"Functional dyspepsia is a common but serious medical syndrome that can induce weight loss and food aversion and may be associated with increased risks of hospitalization and death. It probably comprises several different and as yet incompletely characterized disorders. Patients with local mucosal microinflammation driven by an aberrant Th2 response may represent an important subgroup. There is overlap with other gastrointestinal syndromes, particularly irritable bowel syndrome and gastroesophage...",Correspondence
41467671,More on Long-Term Outcomes of the DanGer Shock Trial. Reply.,"M&#xf8;ller Jacob E, Beske Rasmus P, Hassager Christian",The New England journal of medicine,2025 12,10.1056/NEJMc2514551,,Correspondence
41467670,More on Long-Term Outcomes of the DanGer Shock Trial.,"Ferlini Marco, Pontremoli Silvia Miette",The New England journal of medicine,2025 12,10.1056/NEJMc2514551,,Correspondence
41467669,More on Long-Term Outcomes of the DanGer Shock Trial.,"Thevathasan Tharusan, Zeymer Uwe, Thiele Holger",The New England journal of medicine,2025 12,10.1056/NEJMc2514551,,Correspondence
41467668,Monoclonal Gammopathy of Undetermined Significance. Reply.,"Rajkumar S Vincent, Kumar Shaji",The New England journal of medicine,2025 12,10.1056/NEJMc2515512,,Correspondence
41467667,Monoclonal Gammopathy of Undetermined Significance.,"Istaiti Majdolen, Landgren Ola, Zimran Ari",The New England journal of medicine,2025 12,10.1056/NEJMc2515512,,Correspondence
41467666,Monoclonal Gammopathy of Undetermined Significance.,Keren David F,The New England journal of medicine,2025 12,10.1056/NEJMc2515512,,Correspondence
41467665,Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. Reply.,"Bergmark Brian A, Marston Nicholas A, Sabatine Marc S",The New England journal of medicine,2025 12,10.1056/NEJMc2515639,,Correspondence
41467664,Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia.,Tomlinson Brian,The New England journal of medicine,2025 12,10.1056/NEJMc2515639,,Correspondence
41467663,Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia.,"Perlemuter Gabriel, Voican Cosmin",The New England journal of medicine,2025 12,10.1056/NEJMc2515639,,Correspondence
41467662,Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. Reply.,"Bavendiek Udo, Gro&#xdf;hennig Annika, Bauersachs Johann",The New England journal of medicine,2025 12,10.1056/NEJMc2515452,,Correspondence
41467661,Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.,Shamsulddin Ahmed B,The New England journal of medicine,2025 12,10.1056/NEJMc2515452,,Correspondence
41467660,Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.,Curtain James P,The New England journal of medicine,2025 12,10.1056/NEJMc2515452,,Correspondence
41467659,Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.,"Boulin Mathieu, Cransac-Miet Am&#xe9;lie, Tannenbaum Cara",The New England journal of medicine,2025 12,10.1056/NEJMc2515452,,Correspondence
41467658,Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.,"Hothi Sandeep S, Lau Clement, Tan Lip Bun",The New England journal of medicine,2025 12,10.1056/NEJMc2515452,,Correspondence
41467657,Direct-Acting Antiviral Agents in Hepatitis C-Associated Indolent Lymphomas.,"Merli Michele, Genuardi Elisa, Zibellini Silvia, Rattotti Sara, Spina Michele",The New England journal of medicine,2025 12,10.1056/NEJMc2513023,,Correspondence
41467651,Cardiogenic Shock.,"Thiele Holger, Hassager Christian",The New England journal of medicine,2025 12,10.1056/NEJMra2312086,"Cardiogenic shock is characterized by depression of cardiac function that leads to low blood pressure, coronary ischemia, and further decreased cardiac contractility resulting in tissue hypoxemia. The condition is associated with high early mortality, approaching 50%, which is largely influenced by the underlying etiologic factors. In infarct-related cardiogenic shock, rapid restoration of coronary blood flow substantially reduces mortality. Mechanical circulatory support devices offer hemodynam...",Original Article
41467650,An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis II.,"Muenzer Joseph, Burton Barbara K, Harmatz Paul, Rajan Deepa S, Jones Simon A",The New England journal of medicine,2025 12,10.1056/NEJMoa2508681,"Tividenofusp alfa, comprising iduronate-2-sulfatase fused to an engineered transferrin receptor-binding Fc domain, has been developed to treat neurologic and peripheral manifestations of mucopolysaccharidosis type II (MPS II), a rare lysosomal disorder causing progressive multisystem and neurologic decline.",Original Article
41406460,Spiderweb-like Vessels in Retinopathy of Prematurity. Reply.,"Zhao Xinyu, Zhang Guoming",The New England journal of medicine,2025 12,10.1056/NEJMc2513189,,Correspondence
41406459,Spiderweb-like Vessels in Retinopathy of Prematurity.,"Peng Jie, Zhao Peiquan",The New England journal of medicine,2025 12,10.1056/NEJMc2513189,,Correspondence
41406458,Allogeneic Beta Cells with No Immunosuppression. Reply.,"Carlsson Per-Ola, Deuse Tobias, Schrepfer Sonja",The New England journal of medicine,2025 12,10.1056/NEJMc2516172,,Correspondence
41406457,Allogeneic Beta Cells with No Immunosuppression.,"Kumar Pawan, Kenwar Deepesh B, Sharma Ashish",The New England journal of medicine,2025 12,10.1056/NEJMc2516172,,Correspondence
41406456,Aficamten Monotherapy for Hypertrophic Cardiomyopathy. Reply.,"Garcia-Pavia Pablo, Maron Martin S, Lewis Gregory D",The New England journal of medicine,2025 12,10.1056/NEJMc2514558,,Correspondence
41406455,Aficamten Monotherapy for Hypertrophic Cardiomyopathy.,"Mapelli Massimo, Willixhofer Robin, Agostoni Piergiuseppe",The New England journal of medicine,2025 12,10.1056/NEJMc2514558,,Correspondence
41406454,Aficamten Monotherapy for Hypertrophic Cardiomyopathy.,"Ahamed Hisham, Ommen Steve R, Rowin Ethan J",The New England journal of medicine,2025 12,10.1056/NEJMc2514558,,Correspondence
41406453,A Case of Cervical Ectopic Pregnancy after the Dobbs Decision.,"Diniz Clarissa P, Bal Japjot, Nelson Hallie, Findley Molly",The New England journal of medicine,2025 12,10.1056/NEJMc2508182,,Correspondence
41406445,Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis.,"Meya David B, Cresswell Fiona V, Dai Biyue, Engen Nicole, Naidoo Kogieleum",The New England journal of medicine,2025 12,10.1056/NEJMoa2502866,"Tuberculous meningitis is often lethal, and many survivors have disabilities despite antimicrobial treatment and adjunctive glucocorticoid therapy. Standard-dose rifampin has limited central nervous system penetration. Whether high-dose rifampin could improve survival outcomes is unknown.",Correspondence
41406444,Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.,"Nicholls Stephen J, Pavo Imre, Bhatt Deepak L, Buse John B, Del Prato Stefano",The New England journal of medicine,2025 12,10.1056/NEJMoa2505928,"Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on glycemic control and body weight. The effects on cardiovascular outcomes are uncertain.",Original Article
41370815,Abdominojugular Reflux Test. Reply.,"Bent Stephen, Dhaliwal Gurpreet",The New England journal of medicine,2025 12,10.1056/NEJMc2514311,,Correspondence
41370814,Abdominojugular Reflux Test.,"Lehl Sarabmeet, Gupta Monica, Cruz Sanjay D",The New England journal of medicine,2025 12,10.1056/NEJMc2514311,,Correspondence
41370813,Oral Semaglutide in Adults with Overweight or Obesity. Reply.,"Wharton Sean, Duque do Vale Ruben, Garvey W Timothy",The New England journal of medicine,2025 12,10.1056/NEJMc2515109,,Correspondence
41370812,Oral Semaglutide in Adults with Overweight or Obesity.,"Liu Hongquan, Sun Fengze, Wu Jitao",The New England journal of medicine,2025 12,10.1056/NEJMc2515109,,Correspondence
41370811,Oral Semaglutide in Adults with Overweight or Obesity.,"Kermansaravi Mohammad, Cohen Ricardo V",The New England journal of medicine,2025 12,10.1056/NEJMc2515109,,Correspondence
41370810,Extended Treatment of Provoked Venous Thromboembolism. Reply.,Piazza Gregory,The New England journal of medicine,2025 12,10.1056/NEJMc2515264,,Correspondence
41370809,Extended Treatment of Provoked Venous Thromboembolism.,Tazi Mezalek Zoubida,The New England journal of medicine,2025 12,10.1056/NEJMc2515264,,Correspondence
41370808,Extended Treatment of Provoked Venous Thromboembolism.,Calvello Jonathan,The New England journal of medicine,2025 12,10.1056/NEJMc2515264,,Correspondence
41370807,Extended Treatment of Provoked Venous Thromboembolism.,"Jacob Sibele C B, Benedetto Igor G, Gazzana Marcelo B",The New England journal of medicine,2025 12,10.1056/NEJMc2515264,,Correspondence
41370806,Extended Treatment of Provoked Venous Thromboembolism.,"Demirci &#x15e;ahin Ay&#x15f;e, &#x15e;ahin U&#x11f;ur",The New England journal of medicine,2025 12,10.1056/NEJMc2515264,,Correspondence
41370805,Molecular Evidence of Multiorgan Damage in Patients with Immune-Related Adverse Events.,"Wang Yuxuan, Li Howard L, Bettegowda Chetan, Kinzler Kenneth W, Papadopoulos Nickolas",The New England journal of medicine,2025 12,10.1056/NEJMc2513984,,Correspondence
41370739,Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.,"Loibl Sibylle, Park Yeon Hee, Shao Zhiming, Huang Chiun-Sheng, Barrios Carlos",The New England journal of medicine,2025 12,10.1056/NEJMoa2514661,Patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer and residual disease after neoadjuvant therapy are at high risk for recurrence.,Original Article
41369227,Ketamine or Etomidate for Tracheal Intubation of Critically Ill Adults.,"Casey Jonathan D, Seitz Kevin P, Driver Brian E, Gibbs Kevin W, Ginde Adit A",The New England journal of medicine,2025 12,10.1056/NEJMoa2511420,"For critically ill adults undergoing tracheal intubation, observational studies suggest that the use of etomidate to induce anesthesia may increase the risk of death. Whether the use of ketamine rather than etomidate decreases the risk of death is uncertain.",Original Article
41363805,Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.,"Chiesa Robert, Georgiadis Christos, Rashed Hebatalla, Preece Roland, Hardefeldt Prudence",The New England journal of medicine,2026 01,10.1056/NEJMoa2505478,"CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base-edited anti-CD7 CAR (BE-CAR7) T cells with triple C&#x2192;T deamination-mediated knockouts of TCR&#x3b1;&#x3b2;, CD52, and CD7 have been reported previously.",Original Article
41363801,Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.,"Costa Luciano J, Bahlis Nizar J, Perrot Aurore, Nooka Ajay K, Lu Jin",The New England journal of medicine,2025 12,10.1056/NEJMoa2514663,"In a phase 1-2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma. Daratumumab, a monoclonal antibody targeting CD38 protein, has shown survival benefit in patients with multiple myeloma.",Correspondence
41363800,Ianalumab plus Eltrombopag in Immune Thrombocytopenia.,"Cuker Adam, Stauch Thomas, Cooper Nichola, Al-Samkari Hanny, Michel Marc",The New England journal of medicine,2025 12,10.1056/NEJMoa2515168,"Current second-line treatments for immune thrombocytopenia (ITP) require long-term administration. Ianalumab, a monoclonal antibody targeting B cells, is being assessed as a short-course second-line therapy in ITP.",Correspondence
41358601,Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.,"Al-Sawaf Othman, Stumpf Janina, Zhang Can, Simon Florian, Bosch Francesc",The New England journal of medicine,2025 12,10.1056/NEJMoa2515458,Treatment of chronic lymphocytic leukemia (CLL) currently consists of two main approaches - continuous therapy with Bruton's tyrosine kinase inhibitors and fixed-duration regimens combining venetoclax with either CD20 antibodies or Bruton's tyrosine kinase inhibitors. Comparisons of these two therapeutic approaches are lacking.,Correspondence
41358590,Prime Editing for p47phox-Deficient Chronic Granulomatous Disease.,"Gori Jennifer L, Haddad Elie, Frangoul Haydar, Kohn Donald B, Morris Emma C",The New England journal of medicine,2025 12,10.1056/NEJMoa2509807,"Chronic granulomatous disease (CGD) is a severe monogenic immunodeficiency caused by damaging variants in genes required for microbicidal NADPH oxidase activity. Autosomal recessive p47phox-deficient CGD (p47-CGD) is predominantly caused by a two-nucleotide deletion in exon 2 (delGT) of NCF1. We developed PM359, an autologous CD34+ hematopoietic stem-cell therapy in which prime editing is used to correct delGT. Two participants received PM359 after myeloid conditioning with busulfan: neutrophils...",Original Article
41358585,Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B.,"Pipe Steven W, Miesbach Wolfgang, Recht Michael, Leebeek Frank W G, Key Nigel S",The New England journal of medicine,2025 12,10.1056/NEJMoa2514332,"Prophylactic treatment for hemophilia B necessitates lifelong, regular intravenous factor IX infusions. Gene therapy offers the possibility of a single-dose treatment that produces durable endogenous factor IX expression and disease control. Etranacogene dezaparvovec comprises an adeno-associated virus serotype 5 (AAV5) vector and the highly active Padua factor IX variant. The primary analysis of this study showed that etranacogene dezaparvovec reduced annualized bleeding rates and adverse event...",Original Article
41358582,Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.,"Kumar Shaji, Mateos Mar&#xed;a-Victoria, Ye Jing Christine, Atrash Shebli, Magen Hila",The New England journal of medicine,2025 12,10.1056/NEJMoa2514752,"Patients with plasmacytomas that are noncontiguous with bone marrow (true extramedullary myeloma) are at high risk for disease progression or relapse. Phase 1 of the RedirecTT-1 study showed promising efficacy with dual-antigen targeting of myeloma with talquetamab (anti-G protein-coupled receptor family C group 5 member D) plus teclistamab (anti-B-cell maturation antigen) in patients with triple-class-exposed relapsed or refractory multiple myeloma, including those with true extramedullary myel...",Correspondence
41337735,Noninferiority of One HPV Vaccine Dose to Two Doses.,"Kreimer Aim&#xe9;e R, Porras Carolina, Liu Danping, Hildesheim Allan, Carvajal Loretto J",The New England journal of medicine,2025 12,10.1056/NEJMoa2506765,"Multidose human papillomavirus (HPV) vaccination is efficacious, yet the vaccine has been underused globally. Emerging data suggest that a single dose may provide protection. Whether a single dose of HPV vaccine would provide similar protection to two doses is uncertain.",Original Article
41337731,Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia. Reply.,"Munir Talha, Cairns David A, Hillmen Peter",The New England journal of medicine,2025 12,10.1056/NEJMc2515262,,Correspondence
41337730,Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.,"Wang Yun, Zhu Ziang, Liang Yang",The New England journal of medicine,2025 12,10.1056/NEJMc2515262,,Correspondence
41337729,Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.,Fleischman Roger A,The New England journal of medicine,2025 12,10.1056/NEJMc2515262,,Correspondence
41337728,"Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes. Reply.","Rosenstock Julio, Cox David, Denning Max",The New England journal of medicine,2025 12,10.1056/NEJMc2515117,,Correspondence
41337727,"Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes.","Xie Xuemei, Xuan Xiuping",The New England journal of medicine,2025 12,10.1056/NEJMc2515117,,Correspondence
41337726,"Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes.",Jagarlapudi Siva P,The New England journal of medicine,2025 12,10.1056/NEJMc2515117,,Correspondence
41337725,"Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes.",Nagaoka Tadasu,The New England journal of medicine,2025 12,10.1056/NEJMc2515117,,Correspondence
41337724,Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial. Reply.,"Jastreboff Ania M, Ryan Donna H, Pannacciulli Nicola",The New England journal of medicine,2025 12,10.1056/NEJMc2514331,,Correspondence
41337723,Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial.,"Muskiet Marcel H A, Smits Mark M",The New England journal of medicine,2025 12,10.1056/NEJMc2514331,,Correspondence
41337722,Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial.,Liu Qiyuan K,The New England journal of medicine,2025 12,10.1056/NEJMc2514331,,Correspondence
41337721,Stability of Avian Influenza A(H5N1) Virus in Milk from Infected Cows and Virus-Spiked Milk.,"Guan Lizheng, Pattinson David, Eisfeld Amie J, Wang Tong, Halfmann Peter J",The New England journal of medicine,2025 12,10.1056/NEJMc2502494,,Correspondence
41337715,Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN.,"Fakhouri Fadi, Bomback Andrew S, Ariceta Gema, Delmas Yahsou, Dixon Bradley P",The New England journal of medicine,2025 12,10.1056/NEJMoa2501510,"C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis (MPGN) generally result in glomerular C3 deposition and irreversible kidney damage. The efficacy and safety of pegcetacoplan, a C3 and C3b inhibitor, in persons with C3 glomerulopathy or primary immune-complex MPGN are unclear.",Original Article
41297020,Medications for Opioid Use Disorder in County Jails - Outcomes after Release. Reply.,"Friedmann Peter D, Evans Elizabeth A",The New England journal of medicine,2025 11,10.1056/NEJMc2514548,,Correspondence
41297019,Medications for Opioid Use Disorder in County Jails - Outcomes after Release.,"Berk Justin, Rich Josiah",The New England journal of medicine,2025 11,10.1056/NEJMc2514548,,Correspondence
41297018,Cardiac Rehabilitation for Older Patients. Reply.,"Tonet Elisabetta, Campo Gianluca",The New England journal of medicine,2025 11,10.1056/NEJMc2514544,,Correspondence
41297017,Cardiac Rehabilitation for Older Patients.,"Yang Chen Die, Wang Xiao Qun",The New England journal of medicine,2025 11,10.1056/NEJMc2514544,,Correspondence
41297016,Cardiac Rehabilitation for Older Patients.,"Tahir Rehab Bint E, Midhat Syeda, Afzal Rubia",The New England journal of medicine,2025 11,10.1056/NEJMc2514544,,Correspondence
41297015,Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer. Reply.,"Martling Anna, Myrberg Ida Hed, Lindberg Johan",The New England journal of medicine,2025 11,10.1056/NEJMc2515071,,Correspondence
41297014,Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer.,"Guo Qian, Zhao Yulin, Yin Chengliang",The New England journal of medicine,2025 11,10.1056/NEJMc2515071,,Correspondence
41297013,Osilodrostat for Bilateral Adrenal Hypercortisolism in Primary Aldosteronism.,"Richa Carine, Lacroix Andr&#xe9;, Young Jacques",The New England journal of medicine,2025 11,10.1056/NEJMc2512144,,Correspondence
41297012,Adrenal Aldosterone Synthase Expression Imaging in Primary Aldosteronism.,"&#xc5;rstad Erik, Sander Kerstin, Kurzawinski Tom R, Anderson Cameron, Buhidma Yazead",The New England journal of medicine,2025 12,10.1056/NEJMc2507481,,Correspondence
41297007,Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia.,"Al-Samkari Hanny, Hessels Josefien, Riera-Mestre Antoni, Dupuis-Girod Sophie, Van Zele Thibaut",The New England journal of medicine,2025 11,10.1056/NEJMoa2504411,"Hereditary hemorrhagic telangiectasia (HHT) can cause recurrent, severe epistaxis, as well as anemia and reduced quality of life. The disease remains without licensed therapies worldwide.",Original Article
41297006,Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human Infection Model.,"Durbin Anna P, Van Wesenbeeck Liesbeth, Pierce Kristen K, Herrera-Taracena Guillermo, Ebone Laura",The New England journal of medicine,2025 11,10.1056/NEJMoa2500179,Approximately half the worldwide population is at risk for dengue. No antiviral prophylaxis or treatment options are available.,Correspondence
41269206,Medical Management and Revascularization for Asymptomatic Carotid Stenosis.,"Brott Thomas G, Howard George, Lal Brajesh K, Voeks Jenifer H, Turan Tanya N",The New England journal of medicine,2025 11,10.1056/NEJMoa2508800,"Improvements in medical therapy, carotid-artery stenting, and carotid endarterectomy call into question the preferred management of asymptomatic carotid stenosis. Whether adding revascularization to intensive medical management would provide greater benefit than intensive medical management alone is unclear.",Original Article
41259774,Pathogenesis of Heparin-Induced Thrombocytopenia. Reply.,"Nazy Ishac, Treverton Jared, Arnold Donald M",The New England journal of medicine,2025 11,10.1056/NEJMc2514329,,Correspondence
41259773,Pathogenesis of Heparin-Induced Thrombocytopenia.,"An Zhuo-Yu, Zhang Xiao-Hui",The New England journal of medicine,2025 11,10.1056/NEJMc2514329,,Correspondence
41259772,Pathogenesis of Heparin-Induced Thrombocytopenia.,Cohn Danny M,The New England journal of medicine,2025 11,10.1056/NEJMc2514329,,Correspondence
41259771,Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. Reply.,"Forde Patrick M, Provencio Mariano, Girard Nicolas",The New England journal of medicine,2025 11,10.1056/NEJMc2513316,,Correspondence
41259770,Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.,"Li Xuesong, Mu Xiangdong",The New England journal of medicine,2025 11,10.1056/NEJMc2513316,,Correspondence
41259769,Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply.,"Davies Melanie J, Broholm Christa, Garvey W Timothy",The New England journal of medicine,2025 11,10.1056/NEJMc2513141,,Correspondence
41259768,Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply.,"Garvey W Timothy, Osorto Contreras Cynthia Karenina, Davies Melanie J",The New England journal of medicine,2025 11,10.1056/NEJMc2513141,,Correspondence
41259767,Cagrilintide-Semaglutide in Adults with Overweight or Obesity.,"Chi Hao, Yang Hua, Deng Youping",The New England journal of medicine,2025 11,10.1056/NEJMc2513141,,Correspondence
41259766,Cagrilintide-Semaglutide in Adults with Overweight or Obesity.,"Lnu Vivek, Noor Fatima",The New England journal of medicine,2025 11,10.1056/NEJMc2513141,,Correspondence
41259765,Cagrilintide-Semaglutide in Adults with Overweight or Obesity.,"Krakauer Jesse C, Krakauer Nir Y",The New England journal of medicine,2025 11,10.1056/NEJMc2513141,,Correspondence
41259764,Cagrilintide-Semaglutide in Adults with Overweight or Obesity.,"Fogacci Federica, Cicero Arrigo F G",The New England journal of medicine,2025 11,10.1056/NEJMc2513141,,Correspondence
41259756,"Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine.","Fitz-Patrick David, McVinnie Donald S, Jackson Lisa A, Crowther Graham, Geevarughese Anita",The New England journal of medicine,2025 11,10.1056/NEJMoa2416779,Influenza remains a major health burden despite the use of licensed vaccines. Nucleoside-modified messenger RNA (modRNA) influenza vaccines have shown promising immunogenicity against influenza and an acceptable safety profile in a phase 1-2 trial.,Correspondence
41259754,A Multicomponent Intervention to Improve Maternal Infection Outcomes.,"Lissauer David, Gadama Luis, Waitt Catriona, Whyte Sonia, Burnside Girvan",The New England journal of medicine,2025 11,10.1056/NEJMoa2512698,"Maternal infection and sepsis are major causes of maternal death and severe illness worldwide, particularly in low- and middle-income countries. Inconsistent implementation of evidence-based recommendations for infection prevention and management and delays in detection and treatment of maternal sepsis contribute to the number of preventable deaths.",Original Article
41223378,Educational Strategies for Clinical Supervision of Artificial Intelligence Use. Reply.,"Abdulnour Raja-Elie E, Gin Brian, Boscardin Christy K",The New England journal of medicine,2025 11,10.1056/NEJMc2513937,,Correspondence
41223377,Educational Strategies for Clinical Supervision of Artificial Intelligence Use.,"Alves Jos&#xe9;, Alves Paulo",The New England journal of medicine,2025 11,10.1056/NEJMc2513937,,Correspondence
41223376,Educational Strategies for Clinical Supervision of Artificial Intelligence Use.,"Firoz Farhat, Srivastava Jyoti, Anwar Firoz",The New England journal of medicine,2025 11,10.1056/NEJMc2513937,,Correspondence
41223375,Educational Strategies for Clinical Supervision of Artificial Intelligence Use.,Yoshida Kazunari,The New England journal of medicine,2025 11,10.1056/NEJMc2513937,,Correspondence
41223374,Adjuvant Cemiplimab in Cutaneous Squamous-Cell Carcinoma. Reply.,"Rischin Danny, Porceddu Sandro, Day Fiona",The New England journal of medicine,2025 11,10.1056/NEJMc2513309,,Correspondence
41223373,Adjuvant Cemiplimab in Cutaneous Squamous-Cell Carcinoma.,"Kim Dahyeon, Babaei Nickoulet, Wu Jashin J",The New England journal of medicine,2025 11,10.1056/NEJMc2513309,,Correspondence
41223372,Acute Normovolemic Hemodilution in Cardiac Surgery. Reply.,"Monaco Fabrizio, Bonizzoni Matteo Aldo, Landoni Giovanni",The New England journal of medicine,2025 11,10.1056/NEJMc2513087,,Correspondence
41223371,Acute Normovolemic Hemodilution in Cardiac Surgery.,Ahmed Andaleeb A,The New England journal of medicine,2025 11,10.1056/NEJMc2513087,,Correspondence
41223370,Acute Normovolemic Hemodilution in Cardiac Surgery.,Tamura Takahiro,The New England journal of medicine,2025 11,10.1056/NEJMc2513087,,Correspondence
41223369,A Mammarenavirus Close to Lassa Virus in a Patient with Meningoencephalitis.,"Baize Sylvain, Pannetier Delphine, Rodriguez Christophe, Josset Laurence, de Laval Franck",The New England journal of medicine,2025 11,10.1056/NEJMc2505127,,Correspondence
41211954,Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction.,"Kristensen Anna Meta Dyrvig, Rossello Xavier, Atar Dan, Yndigegn Troels, Kimura Takeshi",The New England journal of medicine,2025 11,10.1056/NEJMoa2512686,The benefit of beta-blockers after myocardial infarction in patients with a preserved left ventricular ejection fraction (LVEF) is unclear.,Original Article
41211945,Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3.,"Laffin Luke J, Nicholls Stephen J, Scott Russell S, Clifton Peter M, Baker John",The New England journal of medicine,2025 11,10.1056/NEJMoa2511778,Angiopoietin-like protein 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases. ANGPTL3 loss-of-function genetic variants are associated with decreased levels of low-density lipoprotein cholesterol and triglycerides and a decreased lifetime risk of atherosclerotic cardiovascular disease.,Original Article
41211943,A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D.,"Asselah Tarik, Chattergoon Michael A, Jucov Alina, Streinu-Cercel Anca, Lampertico Pietro",The New England journal of medicine,2025 11,10.1056/NEJMoa2508827,Both tobevibart (a monoclonal antibody) and elebsiran (a small interfering RNA) target hepatitis B virus surface antigen (HBsAg). Their efficacy and safety in the treatment of chronic hepatitis D virus (HDV) infection are unknown.,Correspondence
41211931,Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation.,"Verma Atul, Birnie David H, Jiang Chenyang, Heidb&#xfc;chel Hein, Hindricks Gerhard",The New England journal of medicine,2025 11,10.1056/NEJMoa2509688,Whether successful catheter ablation for atrial fibrillation eliminates the need for long-term oral anticoagulant therapy is unknown.,Original Article
41211929,Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.,"Perkovic Vlado, Trimarchi Hern&#xe1;n, Tesar Vladimir, Lafayette Richard, Wong Muh Geot",The New England journal of medicine,2025 11,10.1056/NEJMoa2512133,"The cytokine A proliferation-inducing ligand (APRIL) is considered a key driver of the pathogenesis of IgA nephropathy. Sibeprenlimab, a humanized IgG2 monoclonal antibody, selectively binds to and inhibits APRIL.",Original Article
41211925,Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.,"Bohula Erin A, Marston Nicholas A, Bhatia Ajay K, De Ferrari Gaetano M, Leiter Lawrence A",The New England journal of medicine,2026 01,10.1056/NEJMoa2514428,"The proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, stroke, or symptomatic peripheral artery disease. The effect of evolocumab on the risk of MACE among patients without a previous myocardial infarction or stroke is unknown.",Original Article
41211918,Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.,"Marston Nicholas A, Bergmark Brian A, Alexander Veronica J, Prohaska Thomas A, Kang Yu Mi",The New England journal of medicine,2025 11,10.1056/NEJMoa2512761,"Patients with severe hypertriglyceridemia have an increased risk of acute pancreatitis. The efficacy and safety of olezarsen, an antisense oligonucleotide targeting apolipoprotein C-III messenger RNA, have not been established in this population.",Original Article
41211917,Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.,"Lee Seung-Jun, Yu Hee Tae, Lee Yong-Joon, Lee Sang-Hyup, Heo Jung Ho",The New England journal of medicine,2025 11,10.1056/NEJMoa2512091,"Despite guideline recommendations, evidence for the use of non-vitamin K antagonist oral anticoagulant (NOAC) monotherapy in patients with atrial fibrillation after implantation of a drug-eluting stent remains limited.",Original Article
41201837,Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis.,"Lok Charmaine E, Farkouh Michael, Hemmelgarn Brenda R, Moist Louise M, Polkinghorne Kevan R",The New England journal of medicine,2026 01,10.1056/NEJMoa2513032,"Cardiovascular disease is the leading cause of death in patients receiving hemodialysis, yet effective preventive therapies remain limited. Supplementation with n-3 polyunsaturated fatty acids, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), may have cardiovascular benefits in the general population, but efficacy among patients receiving hemodialysis is uncertain.",Original Article
41196369,A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy.,"Lafayette Richard, Barbour Sean J, Brenner Robert M, Campbell Kirk N, Doan Tom",The New England journal of medicine,2025 11,10.1056/NEJMoa2510198,"IgA nephropathy, the most common primary glomerulopathy worldwide, is a kidney disorder of B-cell origin characterized by mesangial accumulation of IgA-containing immune complexes. In at least 50% of patients, IgA nephropathy leads to kidney failure or death within 10 to 20 years after diagnosis. Atacicept is a native human transmembrane activator and calcium-modulator and cyclophilin-ligand interactor (TACI)-Fc fusion protein that inhibits two key immunoregulatory cytokines - B-cell activating ...",Original Article
41191955,Testosterone for Middle-Aged and Older Men with Hypogonadism. Reply.,"Bhasin Shalender, Snyder Peter J",The New England journal of medicine,2025 11,10.1056/NEJMc2512879,,Correspondence
41191954,Testosterone for Middle-Aged and Older Men with Hypogonadism.,Campodonico Fabio,The New England journal of medicine,2025 11,10.1056/NEJMc2512879,,Correspondence
41191953,Testosterone for Middle-Aged and Older Men with Hypogonadism.,"Jiesisibieke Zhu Liduzi, Schooling C Mary",The New England journal of medicine,2025 11,10.1056/NEJMc2512879,,Correspondence
41191952,Testosterone for Middle-Aged and Older Men with Hypogonadism.,Malozowski Saul,The New England journal of medicine,2025 11,10.1056/NEJMc2512879,,Correspondence
41191951,Vepdegestrant in Advanced Breast Cancer. Reply.,Campone Mario,The New England journal of medicine,2025 11,10.1056/NEJMc2512877,,Correspondence
41191950,Vepdegestrant in Advanced Breast Cancer.,"Shimoi Tatsunori, Yonemori Kan",The New England journal of medicine,2025 11,10.1056/NEJMc2512877,,Correspondence
41191949,Vepdegestrant in Advanced Breast Cancer.,"Trovato Giovanni, Tortora Giampaolo",The New England journal of medicine,2025 11,10.1056/NEJMc2512877,,Correspondence
41191948,Cold Perfusion vs. Static Cold Storage of Deceased-Donor Kidneys - at 10 Years.,"Schutter Rianne, Moers Cyril, Jochmans Ina, Gallinat Anja, Paul Andreas",The New England journal of medicine,2025 11,10.1056/NEJMc2406608,,Correspondence
41191941,Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate.,"Malkin Elissa, Zaric Marija, Kieh Mark, Baden Lindsey R, Fitz-Patrick David",The New England journal of medicine,2025 11,10.1056/NEJMoa2501073,"No vaccine is currently available for Lassa fever, a viral hemorrhagic disease that is estimated to cause thousands of deaths each year in western Africa. A replication-competent recombinant vesicular stomatitis virus-vectored vaccine encoding a Lassa virus (LASV) glycoprotein complex, rVSV&#x394;G-LASV-GPC, has been developed, but data on its safety and immunogenicity are limited.",Correspondence
41191940,Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents.,"Bissonnette Robert, Soung Jennifer, Hebert Adelaide A, Pink Andrew E, Pinter Andreas",The New England journal of medicine,2025 11,10.1056/NEJMoa2504187,"Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the treatment of plaque psoriasis.",Correspondence
41191939,Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer.,"Kunkler Ian H, Russell Nicola S, Anderson Niall, Sainsbury Richard, Dixon J Michael",The New England journal of medicine,2025 11,10.1056/NEJMoa2412225,The role of postmastectomy chest-wall irradiation in patients with breast cancer classified as pN1 (with involvement of one to three axillary nodes) or pN0 (pathologically node negative) with additional risk factors is uncertain.,Correspondence
41160841,Donor Hearts for Transplantation after Circulatory Death. Reply.,"Kucera John A, Overbey Douglas M, Turek Joseph W",The New England journal of medicine,2025 10,10.1056/NEJMc2511568,,Correspondence
41160840,Donor Hearts for Transplantation after Circulatory Death. Reply.,"Williams Aaron M, Shah Ashish S",The New England journal of medicine,2025 10,10.1056/NEJMc2511568,,Correspondence
41160839,Donor Hearts for Transplantation after Circulatory Death.,"Bernat James L, Delmonico Francis L, Capron Alexander M",The New England journal of medicine,2025 10,10.1056/NEJMc2511568,,Correspondence
41160838,Donor Hearts for Transplantation after Circulatory Death.,de Meijer Vincent E,The New England journal of medicine,2025 10,10.1056/NEJMc2511568,,Correspondence
41160837,Donor Hearts for Transplantation after Circulatory Death.,"Pradegan Nicola, Zanatta Paolo, Gerosa Gino",The New England journal of medicine,2025 10,10.1056/NEJMc2511568,,Correspondence
41160836,Donor Hearts for Transplantation after Circulatory Death.,"Pocar Marco, Boffini Massimo, Rinaldi Mauro",The New England journal of medicine,2025 10,10.1056/NEJMc2511568,,Correspondence
41160835,Donor Hearts for Transplantation after Circulatory Death.,"Ross Lainie Friedman, Ladin Keren, Flescher Andrew",The New England journal of medicine,2025 10,10.1056/NEJMc2511568,,Correspondence
41160834,As-Needed Albuterol-Budesonide in Mild Asthma. Reply.,"LaForce Craig, Papi Alberto, Bacharier Leonard B",The New England journal of medicine,2025 10,10.1056/NEJMc2511561,,Correspondence
41160833,As-Needed Albuterol-Budesonide in Mild Asthma.,Rolla Giovanni,The New England journal of medicine,2025 10,10.1056/NEJMc2511561,,Correspondence
41160832,Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. Reply.,"Agarwal Rajiv, Rossing Peter, Mann Johannes F E",The New England journal of medicine,2025 10,10.1056/NEJMc2513088,,Correspondence
41160831,Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.,"Romagnani Paola, Soler Maria Jose, Fervenza Fernando C",The New England journal of medicine,2025 10,10.1056/NEJMc2513088,,Correspondence
41160830,Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.,Silver Stephen,The New England journal of medicine,2025 10,10.1056/NEJMc2513088,,Correspondence
41160829,Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.,"Assil Rim, Hough Augustus",The New England journal of medicine,2025 10,10.1056/NEJMc2513088,,Correspondence
41160827,Two-Year Outcomes after Transcatheter Arterialization of the Deep Veins.,"Shishehbor Mehdi H, Dua Anahita, Powell Richard J, Montero-Baker Miguel F, Mart&#xed;nez-Trabal Jorge L",The New England journal of medicine,2025 10,10.1056/NEJMc2507935,,Correspondence
41160821,"Safety, Efficacy, and Immunogenicity of a Salmonella Paratyphi A Vaccine.","McCann Naina, Paganotti Vicentine Margarete, Ebrahimi Narges, Greenland Melanie, Angus Brian",The New England journal of medicine,2025 10,10.1056/NEJMoa2502992,Salmonella enterica serovar Paratyphi A (also known as S. Paratyphi A) is responsible for more than 2 million cases of enteric fever annually. There are no licensed vaccines against S. Paratyphi A.,Correspondence
41160820,A Randomized Trial of Physical Therapy for Meniscal Tear and Knee Pain.,"Katz Jeffrey N, Collins Jamie E, Bisson Leslie, Jones Morgan H, Irrgang James J",The New England journal of medicine,2025 10,10.1056/NEJMoa2503385,"Physical therapy is routinely recommended for knee pain attributed to a degenerative meniscal tear, but its efficacy has not been established.",Correspondence
41160819,European Study of Prostate Cancer Screening - 23-Year Follow-up.,"Roobol Monique J, de Vos Ivo I, M&#xe5;nsson Marianne, Godtman Rebecka A, Talala Kirsi M",The New England journal of medicine,2025 10,10.1056/NEJMoa2503223,"The European Randomized Study of Screening for Prostate Cancer (ERSPC) was initiated in 1993 to assess the effect of prostate-specific antigen (PSA) testing on prostate cancer mortality. Because deaths from prostate cancer are expected to rise worldwide owing to increased life expectancy and population growth, a final analysis of the long-term outcomes of prostate cancer screening is essential to understanding the benefits and harms of PSA testing.",Original Article
41160818,Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.,"Tolaney Sara M, Jiang Zefei, Zhang Qingyuan, Barroso-Sousa Romualdo, Park Yeon Hee",The New England journal of medicine,2025 10,10.1056/NEJMoa2508668,Trastuzumab deruxtecan has shown efficacy in patients with previously treated human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer. The efficacy and safety of trastuzumab deruxtecan in patients with no previous therapy for HER2-positive advanced or metastatic breast cancer are unclear.,Correspondence
41160817,"Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026.","Scott Jake, Abers Michael S, Marwah Harleen K, McCann Nicole C, Meyerowitz Eric A",The New England journal of medicine,2025 12,10.1056/NEJMsa2514268,"Changes in the vaccine advisory process in the United States have disrupted immunization guidance, which reinforces the need for independent evidence review to inform decisions regarding immunization for respiratory viruses during the 2025-2026 season.",Original Article
41159889,A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia.,"Lucinde Ruth K, Gathuri Henry, Mwaniki Paul, Orindi Benedict, Otieno Edwin O",The New England journal of medicine,2025 12,10.1056/NEJMoa2507100,Adjunctive glucocorticoids may reduce mortality among patients with severe community-acquired pneumonia (CAP) in well-resourced settings. Whether these drugs are beneficial in low-resource settings with limited diagnostic and treatment facilities is unclear.,Correspondence
41159885,Deferring Arterial Catheterization in Critically Ill Patients with Shock.,"Muller Gr&#xe9;goire, Contou Damien, Ehrmann Stephan, Martin Ma&#xeb;lle, Andreu Pascal",The New England journal of medicine,2025 11,10.1056/NEJMoa2502136,"In patients with shock, whether noninvasive blood-pressure monitoring is an effective alternative to the recommended use of an arterial catheter is uncertain.",Original Article
41159880,Selective Decontamination of the Digestive Tract during Ventilation in the ICU.,"Cuthbertson Brian H, Billot Laurent, Campbell Marion K, Daneman Nick, Davis Joshua S",The New England journal of medicine,2025 10,10.1056/NEJMoa2506398,"Whether selective decontamination of the digestive tract (SDD) reduces mortality among patients undergoing mechanical ventilation and whether it adversely affects microbial ecology in the intensive care unit (ICU) remain unclear. In an earlier analysis of data from Australia, SDD did not result in a lower incidence of in-hospital death than standard care, but data from the full international trial are needed.",Original Article
41159879,Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction.,"Nijveldt Robin, Maeng Michael, Beijnink Casper W H, Piek Jan J, Al-Lamee Rasha K",The New England journal of medicine,2025 10,10.1056/NEJMoa2512918,The preferred timing of treatment of nonculprit lesions in patients with ST-segment elevation myocardial infarction (STEMI) remains uncertain. A comparison of immediate percutaneous coronary intervention (PCI) guided by instantaneous wave-free ratio (iFR) and deferred PCI guided by cardiac stress magnetic resonance imaging (MRI) in patients with STEMI and multivessel disease is warranted.,Original Article
41144631,Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years.,"Leon Martin B, Mack Michael J, Pibarot Philippe, Hahn Rebecca T, Thourani Vinod H",The New England journal of medicine,2025 10,10.1056/NEJMoa2509766,"Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, outcomes were similar among patients who had undergone transcatheter aortic-valve replacement (TAVR) and those who had undergone surgical aortic-valve replacement. Longer-term assessments of clinical outcomes and valve durability are needed.",Original Article
41124644,Tirzepatide vs. Semaglutide for Obesity Treatment. Reply.,Aronne Louis J,The New England journal of medicine,2025 10,10.1056/NEJMc2510962,,Correspondence
41124643,Tirzepatide vs. Semaglutide for Obesity Treatment.,"Abdullayev Nuran, Sanduleanu Sebastian",The New England journal of medicine,2025 10,10.1056/NEJMc2510962,,Correspondence
41124642,Tirzepatide vs. Semaglutide for Obesity Treatment.,"Muskiet Marcel H A, Winter Elizabeth M, Rensen Patrick C N",The New England journal of medicine,2025 10,10.1056/NEJMc2510962,,Correspondence
41124641,Perioperative Durvalumab in Gastric Cancer. Reply.,"Janjigian Yelena Y, Heilbron Eric, Tabernero Josep",The New England journal of medicine,2025 10,10.1056/NEJMc2511566,,Correspondence
41124640,Perioperative Durvalumab in Gastric Cancer.,Hoeppner Jens,The New England journal of medicine,2025 10,10.1056/NEJMc2511566,,Correspondence
41124639,Perioperative Durvalumab in Gastric Cancer.,Li Shenglong,The New England journal of medicine,2025 10,10.1056/NEJMc2511566,,Correspondence
41124637,Resurgence of Zoonotic Highly Pathogenic Avian Influenza A(H5N1) Virus in Cambodia.,"Siegers Jurre Y, Xie Ruopeng, Edwards Kimberly M, Byrne Alexander M P, Hu Shu",The New England journal of medicine,2025 11,10.1056/NEJMc2504302,,Correspondence
41124632,Common Diseases in Clinical Cohorts - Not Always What They Seem.,"Rahimov Fedik, Jacobs Benjamin M, Lee John S, Mahi Naim A, Blumenfeld Andrew",The New England journal of medicine,2025 10,10.1056/NEJMoa2405459,"Misdiagnosis or underdiagnosis of rare diseases in patients with diagnoses of common diseases can lead to delayed or inappropriate treatments, thereby complicating the management of both rare and common conditions. Despite advances in molecular diagnostic techniques, the effect of rare diseases on the diagnosis of common diseases in research and clinical trials has not been comprehensively investigated.",Correspondence
41124233,"Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.","Cort&#xe9;s Javier, Punie Kevin, Barrios Carlos, Hurvitz Sara A, Schneeweiss Andreas",The New England journal of medicine,2025 11,10.1056/NEJMoa2511734,"Patients with previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer who are not candidates for inhibitors of programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) have limited treatment options.",Correspondence
41124220,"Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC.","Fang Wenfeng, Wu Lin, Meng Xiangjiao, Yao Yu, Zuo Wei",The New England journal of medicine,2025 12,10.1056/NEJMoa2512071,Sacituzumab tirumotecan (sac-TMT) is an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 that has shown significant survival benefits in patients with EGFR-mutated non-small-cell lung cancer (NSCLC) that has progressed after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy.,Original Article
41124218,Belzutifan for Advanced Pheochromocytoma or Paraganglioma.,"Jimenez Camilo, Andreassen Mikkel, Durand Alice, Moog Sophie, Hendifar Andrew",The New England journal of medicine,2025 11,10.1056/NEJMoa2504964,"Pheochromocytoma and paraganglioma are neoplasms originating in the adrenal medulla and extraadrenal paraganglia, respectively. Most cases of metastatic pheochromocytoma and paraganglioma are driven by dysregulation of the hypoxia-inducible factor 2&#x3b1; (HIF-2&#x3b1;) pathway. Belzutifan is a HIF-2&#x3b1; inhibitor that may provide antitumor activity in patients with advanced pheochromocytoma or paraganglioma.",Correspondence
41124210,Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.,"Sheng Xinan, Zeng Gongqian, Zhang Cuijian, Zhang Qingyun, Bian Jiasheng",The New England journal of medicine,2025 12,10.1056/NEJMoa2511648,Human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate monotherapy has shown preliminary clinical efficacy in patients with chemotherapy-refractory HER2-positive locally advanced or metastatic urothelial cancer. Previous data showed promising antitumor activity and safety of HER2-specific disitamab vedotin as monotherapy and when combined with programmed cell death protein 1 (PD-1)-directed immunotherapy in this cancer.,Correspondence
41124204,ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.,"Powles Thomas, Kann Ariel G, Castellano Daniel, Gross-Goupil Marine, Nishiyama Hiroyuki",The New England journal of medicine,2025 12,10.1056/NEJMoa2511885,"Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)-based detection of molecular residual disease may identify patients at high risk for recurrence after cystectomy who can benefit from adjuvant immunotherapy, thus sparing patients at lower risk from unnecessary treatment burden.",Original Article
41124203,Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD.,"Holz Frank G, Le Mer Yannick, Muqit Mahiul M K, Hattenbach Lars-Olof, Cusumano Andrea",The New England journal of medicine,2025 11,10.1056/NEJMoa2501396,Geographic atrophy due to age-related macular degeneration (AMD) is the leading cause of irreversible blindness and affects more than 5 million persons worldwide. No therapies to restore vision in such persons currently exist. The photovoltaic retina implant microarray (PRIMA) system combines a subretinal photovoltaic implant and glasses that project near-infrared light to the implant in order to restore sight to areas of central retinal atrophy.,Correspondence
41124201,Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.,"Shore Neal D, Luz Murilo de Almeida, De Giorgi Ugo, Gleave Martin, Gotto Geoffrey T",The New England journal of medicine,2025 10,10.1056/NEJMoa2510310,"In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis-free survival than leuprolide alone among patients with biochemically recurrent prostate cancer. The final analysis of overall survival has not been reported.",Original Article
41124198,Nivolumab for Resected Stage III or IV Melanoma at 9 Years.,"Ascierto Paolo A, Del Vecchio Michele, Merelli Barbara, Gogas Helen, Arance Ana M",The New England journal of medicine,2025 10,10.1056/NEJMoa2504966,"In the CheckMate 238 trial, patients with resected stage IIIB-C or stage IV melanoma who were treated with nivolumab had longer recurrence-free survival than those who received ipilimumab. Data were needed on longer-term survival.",Original Article
41104938,Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.,"J&#xe4;nne Pasi A, Planchard David, Kobayashi Kunihiko, Yang James Chih-Hsin, Liu Ying",The New England journal of medicine,2025 12,10.1056/NEJMoa2510308,The primary analysis of this trial showed that first-line treatment with osimertinib plus chemotherapy with a platinum-based agent and pemetrexed led to significantly longer progression-free survival than osimertinib monotherapy among patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC). Results from the planned final analysis of overall survival are needed.,Original Article
41104928,Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.,"Le Xiuning, Kim Tae Min, Loong Herbert H, Prelaj Arsela, Goh Boon Cher",The New England journal of medicine,2025 11,10.1056/NEJMoa2511065,"HER2 gene mutations occur in 2 to 4% of patients with non-small-cell lung cancer (NSCLC). Sevabertinib is an oral, reversible tyrosine kinase inhibitor that has shown anti-HER2 activity in preclinical models.",Correspondence
41092342,More about the Phase 2a Study of Baxdrostat in Primary Aldosteronism. Reply.,"Turcu Adina F, Freeman Mason W, Brown Morris J",The New England journal of medicine,2025 10,10.1056/NEJMc2512324,,Correspondence
41092341,More about the Phase 2a Study of Baxdrostat in Primary Aldosteronism.,"Carling Tobias, Scholl Ute I",The New England journal of medicine,2025 10,10.1056/NEJMc2512324,,Correspondence
41092340,Competency-Based Medical Education at the Front Lines of Patient Care. Reply.,"Cooper Dawn, Holmboe Eric S",The New England journal of medicine,2025 10,10.1056/NEJMc2512926,,Correspondence
41092339,Competency-Based Medical Education at the Front Lines of Patient Care.,"Yauy K&#xe9;vin, Roubille Camille",The New England journal of medicine,2025 10,10.1056/NEJMc2512926,,Correspondence
41092338,Competency-Based Medical Education at the Front Lines of Patient Care.,Meyer George W,The New England journal of medicine,2025 10,10.1056/NEJMc2512926,,Correspondence
41092337,Competency-Based Medical Education at the Front Lines of Patient Care.,"Iyer Alexander A, Dubosh Nicole M, Schwartzstein Richard M",The New England journal of medicine,2025 10,10.1056/NEJMc2512926,,Correspondence
41092336,BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease.,"Bucci Laura, B&#xf6;ltz Sebastian, Hagen Melanie, Tur Carlo, N&#xf6;thling Danae-Mona",The New England journal of medicine,2025 10,10.1056/NEJMc2506740,,Correspondence
41092331,Mass Administration of Azithromycin to Infants in Mali to Reduce Mortality.,"Haidara Fadima Cheick, Adubra Laura, Abdou Mahamadou, Alber Dagmar, Ashorn Ulla",The New England journal of medicine,2025 10,10.1056/NEJMoa2504644,"Mass administration of azithromycin to children 1 to 59 months of age has been shown to reduce mortality among infants and children in this age group in some areas of sub-Saharan Africa. The largest effects have appeared to be among infants younger than 12 months of age, within 3 months after treatment; this observation motivated the design of the current trial.",Original Article
41092330,Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency.,"Booth Claire, Masiuk Katelyn, Vazouras Konstantinos, Fernandes Augustine, Xu-Bayford Jinhua",The New England journal of medicine,2025 10,10.1056/NEJMoa2502754,Severe combined immunodeficiency (SCID) due to adenosine deaminase (ADA) deficiency (ADA-SCID) is a life-threatening inborn error of immunity for which lentiviral gene therapy has been investigated in clinical trials.,Correspondence
41092329,A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus.,"van Vollenhoven Ronald F, Wang Li, Merrill Joan T, Liu Yi, Bao Chunde",The New England journal of medicine,2025 10,10.1056/NEJMoa2414719,"Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), showed efficacy in adults with active systemic lupus erythematosus (SLE) in a phase 2b trial when added to standard therapy.",Correspondence
41092328,Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer.,"Tu Hua, Huang He, Li Yanfang, Chen Xiaojun, Wang Chunyan",The New England journal of medicine,2025 10,10.1056/NEJMoa2506267,Limited data are available on survival outcomes after sentinel-lymph-node biopsy alone as compared with lymphadenectomy in cervical cancer.,Original Article
41091060,Toward Same-Day Genome Sequencing in the Critical Care Setting.,"Wojcik Monica H, Larkin Katie, Cipicchio Michelle, Doupnik Austin, Zhao Chen",The New England journal of medicine,2025 12,10.1056/NEJMc2512825,,Correspondence
41085057,DB-OTO Gene Therapy for Inherited Deafness.,"Valayannopoulos Vassili, Bance Manohar, Carvalho Daniela S, Greinwald John H, Harvey Steven A",The New England journal of medicine,2025 10,10.1056/NEJMoa2400521,"Genetic deficiency of otoferlin, a protein critical to synaptic transmission by the sensory hair cells of the ear, causes congenital deafness. Medicines to treat the condition are lacking; children typically receive cochlear implants. DB-OTO is a dual adeno-associated virus 1 gene therapy that delivers human OTOF complementary DNA (encoding otoferlin) regulated by a hair cell-specific promoter.",Correspondence
41061247,Case 17-2025: A Man with Respiratory Failure and Shock after Kidney Transplantation. Reply.,"Kotton Camille N, Safa Kassem, Sanders Alan M",The New England journal of medicine,2025 10,10.1056/NEJMc2510614,,Correspondence
41061246,Case 17-2025: A Man with Respiratory Failure and Shock after Kidney Transplantation.,"Glazier Alexandra K, Delmonico Francis L",The New England journal of medicine,2025 10,10.1056/NEJMc2510614,,Correspondence
41061245,Clearance of Squamous-Cell Carcinoma by Restoring T-Cell Receptor Signaling. Reply.,"Lisco Andrea, Starrett Gabriel J, Brownell Isaac",The New England journal of medicine,2025 10,10.1056/NEJMc2512150,,Correspondence
41061244,Clearance of Squamous-Cell Carcinoma by Restoring T-Cell Receptor Signaling.,"Gupta Khushi, Tognaccini Chiara, Wu Jashin J",The New England journal of medicine,2025 10,10.1056/NEJMc2512150,,Correspondence
41061243,Diphtheria Outbreak among Migrants in Europe. Reply.,"Hoefer Andreas, Brisse Sylvain",The New England journal of medicine,2025 11,10.1056/NEJMc2510099,,Correspondence
41061242,Diphtheria Outbreak among Migrants in Europe.,"Georgakopoulou Theano, Tsiodras Sotirios",The New England journal of medicine,2025 11,10.1056/NEJMc2510099,,Correspondence
41061241,Diphtheria Outbreak among Migrants in Europe.,"Brohi Fareeda, Saif Misbah",The New England journal of medicine,2025 11,10.1056/NEJMc2510099,,Correspondence
41061240,Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes. Reply.,"Rosenstock Julio, Carr Molly C, Child Christopher J",The New England journal of medicine,2025 10,10.1056/NEJMc2511881,,Correspondence
41061239,Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes.,"Samajdar Shambo S, Joshi Shashank R, Mukherjee Shatavisa",The New England journal of medicine,2025 10,10.1056/NEJMc2511881,,Correspondence
41061238,Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes.,"Khan Hamed, Adnan Filza",The New England journal of medicine,2025 10,10.1056/NEJMc2511881,,Correspondence
41061237,Specificity of CRISPR-Cas9 Editing in Exagamglogene Autotemcel - Update.,"Yen Angela, Boitano Tony, Zappala Zachary, Mahajan Sudipta, Willems Thomas",The New England journal of medicine,2025 10,10.1056/NEJMc2503294,,Correspondence
41061233,Randomized Trial of Targeted Indoor Spraying to Prevent Aedes-Borne Diseases.,"Dean Natalie E, Crisp Amy M, Che-Mendoza Azael, Kirstein Oscar D, Barrera-Fuentes Gloria A",The New England journal of medicine,2025 10,10.1056/NEJMoa2501069,"Targeted indoor residual spraying focuses insecticide applications on common resting surfaces of Aedes aegypti mosquitoes (an arboviral disease vector) in houses, such as exposed lower sections of walls and under furniture.",Correspondence
41061231,Association of 2024-2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S. Veterans.,"Cai Miao, Xie Yan, Al-Aly Ziyad",The New England journal of medicine,2025 10,10.1056/NEJMoa2510226,"Amid the declining clinical severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and diminishing public uptake of annual coronavirus disease 2019 (Covid-19) vaccines, contemporary evidence on vaccine effectiveness against clinically relevant outcomes is needed.",Original Article
41032722,Cyclophosphamide and Cyclosporin for GVHD Prevention. Reply.,"Curtis David J, Reynolds John, Hill Geoffrey R",The New England journal of medicine,2025 11,10.1056/NEJMc2511563,,Correspondence
41032721,Cyclophosphamide and Cyclosporin for GVHD Prevention.,Akahoshi Yu,The New England journal of medicine,2025 11,10.1056/NEJMc2511563,,Correspondence
41032720,Cyclophosphamide and Cyclosporin for GVHD Prevention.,"Desai Nihar, Mattsson Jonas, Law Arjun D",The New England journal of medicine,2025 10,10.1056/NEJMc2511563,,Correspondence
41032719,Tarlatamab in Small-Cell Lung Cancer. Reply.,"Rudin Charles M, Mountzios Giannis",The New England journal of medicine,2025 11,10.1056/NEJMc2511884,,Correspondence
41032718,Tarlatamab in Small-Cell Lung Cancer.,"Y&#x131;ld&#x131;z O&#x11f;uzhan, Araz Murat",The New England journal of medicine,2025 11,10.1056/NEJMc2511884,,Correspondence
41032717,Trastuzumab Deruxtecan in Gastric Cancer. Reply.,Shitara Kohei,The New England journal of medicine,2025 11,10.1056/NEJMc2511891,,Correspondence
41032716,Trastuzumab Deruxtecan in Gastric Cancer.,Suto Hirotaka,The New England journal of medicine,2025 11,10.1056/NEJMc2511891,,Correspondence
41032715,Nerandomilast in Patients with Pulmonary Fibrosis. Reply.,"Maher Toby M, Richeldi Luca, Zoz Donald F",The New England journal of medicine,2025 11,10.1056/NEJMc2510302,,Correspondence
41032714,Nerandomilast in Patients with Pulmonary Fibrosis.,"Yuji Koichiro, Yuji Wakako",The New England journal of medicine,2025 11,10.1056/NEJMc2510302,,Correspondence
41032713,Nerandomilast in Patients with Pulmonary Fibrosis.,Singh Sheetu,The New England journal of medicine,2025 11,10.1056/NEJMc2510302,,Correspondence
41025556,Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis.,"McLaughlin Vallerie V, Hoeper Marius M, Badesch David B, Ghofrani H Ardeschir, Gibbs J Simon R",The New England journal of medicine,2025 10,10.1056/NEJMoa2508170,"Sotatercept, an activin-signaling inhibitor, reduces morbidity and mortality among patients with long-standing pulmonary arterial hypertension. Its effects in patients with pulmonary arterial hypertension within the first year after diagnosis are unclear.",Original Article
41020514,Hypertonic Saline or Carbocisteine in Bronchiectasis.,"Bradley Judy M, O'Neill Brenda, McAuley Daniel F, Chalmers James D, De Soyza Anthony",The New England journal of medicine,2025 10,10.1056/NEJMoa2510095,"Bronchiectasis guidelines are inconsistent with regard to the effectiveness of mucoactive agents, and their use varies geographically. Large trials are needed to assess safety and effectiveness.",Original Article
41002250,Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy.,"Gillmore Julian D, Gane Ed, T&#xe4;ubel J&#xf6;rg, Pilebro Bj&#xf6;rn, Echaniz-Laguna Andoni",The New England journal of medicine,2025 10,10.1056/NEJMoa2510209,"Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) is a rare, multisystem, progressive, debilitating, and fatal disease characterized by tissue deposition of misfolded transthyretin (TTR) in peripheral nerves. Nexiguran ziclumeran (nex-z) is an investigational in vivo therapy based on CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats and associated Cas9 endonuclease) that is designed to reduce serum TTR levels through selective inactivation of TTR in the liv...",Original Article
40991921,Permethrin-Treated Baby Wraps for the Prevention of Malaria.,"Boyce Ross M, Shook-Sa Bonnie E, Ndizeye Ronnie, Baguma Emmanuel, Giandomenico Dana",The New England journal of medicine,2025 10,10.1056/NEJMoa2501628,Malaria remains a major cause of childhood death in sub-Saharan Africa. We leveraged the traditional practice of mothers carrying children on their backs in cloth wraps to assess whether treating the wraps with an insect repellent might provide a layer of protection against malaria.,Correspondence
40991918,Global Effect of Cardiovascular Risk Factors on Lifetime Estimates. Reply.,"Magnussen Christina, Lorenz Thiess, Blankenberg Stefan",The New England journal of medicine,2025 09,10.1056/NEJMc2511206,,Correspondence
40991917,Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.,"Cordero Lucia, Abasheva Daria, Ortiz Alberto",The New England journal of medicine,2025 11,10.1056/NEJMc2511206,,Correspondence
40991916,Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.,"Akbarpour Samaneh, Azizpour Yosra, Larijani Bagher",The New England journal of medicine,2025 11,10.1056/NEJMc2511206,,Correspondence
40991915,Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.,"Zheng Xiaoni, Zhang Jiameng, Li Zhiyong",The New England journal of medicine,2025 11,10.1056/NEJMc2511206,,Correspondence
40991914,Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.,Cooper Kenneth H,The New England journal of medicine,2025 11,10.1056/NEJMc2511206,,Correspondence
40991913,Cerebral Embolic Protection during TAVI. Reply.,"Kharbanda Rajesh K, Kennedy James, Dodd Matthew",The New England journal of medicine,2025 11,10.1056/NEJMc2510558,,Correspondence
40991912,Cerebral Embolic Protection during TAVI.,"Zhao Mengmeng, Ouyang Fan",The New England journal of medicine,2025 11,10.1056/NEJMc2510558,,Correspondence
40991911,Cerebral Embolic Protection during TAVI.,Sharma Gaurav,The New England journal of medicine,2025 11,10.1056/NEJMc2510558,,Correspondence
40991910,Cerebral Embolic Protection during TAVI.,Kapadia Samir R,The New England journal of medicine,2025 11,10.1056/NEJMc2510558,,Correspondence
40991909,Nonoperative Management of Mismatch Repair-Deficient Tumors. Reply.,"Abida Wassim, Diaz Luis A, Cercek Andrea",The New England journal of medicine,2025 09,10.1056/NEJMc2510154,,Correspondence
40991908,Nonoperative Management of Mismatch Repair-Deficient Tumors.,"Jakubowski Christopher D, Verma Amit, Gartrell Benjamin A",The New England journal of medicine,2025 09,10.1056/NEJMc2510154,,Correspondence
40991907,CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis.,"M&#xfc;ller Fabian, Atreya Raja, V&#xf6;lkl Simon, Aigner Michael, Kretschmann Sascha",The New England journal of medicine,2025 09,10.1056/NEJMc2508023,,Correspondence
40961449,Medical Imaging and Pediatric and Adolescent Hematologic Cancer Risk.,"Smith-Bindman Rebecca, Alber Susan A, Kwan Marilyn L, Pequeno Priscila, Bolch Wesley E",The New England journal of medicine,2025 10,10.1056/NEJMoa2502098,Assessing the risk of radiation-induced hematologic cancer from medical imaging in children and adolescents might support informed decisions on the use of imaging.,Correspondence
40961446,Clesrovimab for Prevention of RSV Disease in Healthy Infants.,"Zar Heather J, Sim&#xf5;es Eric A F, Madhi Shabir A, Ramilo Octavio, Senders Shelly D",The New England journal of medicine,2025 10,10.1056/NEJMoa2502984,Clesrovimab is a long-acting investigational monoclonal antibody against site IV of the respiratory syncytial virus (RSV) fusion protein. Data regarding the safety and efficacy of clesrovimab in healthy infants are needed.,Original Article
40961444,Fetal Hereditary Thrombotic Thrombocytopenic Purpura.,"Arepalli Satya, George James N, Tiwari Nishant R",The New England journal of medicine,2025 09,10.1056/NEJMc2511558,,Correspondence
40961443,Navigating the Discontinuity Crisis in Medical Education. Reply.,"Warm Eric J, Desai Sima S, Bowen Judith L",The New England journal of medicine,2025 09,10.1056/NEJMc2511029,,Correspondence
40961442,Navigating the Discontinuity Crisis in Medical Education.,Rajput Vijay,The New England journal of medicine,2025 09,10.1056/NEJMc2511029,,Correspondence
40961441,Navigating the Discontinuity Crisis in Medical Education.,Eisenson Howard,The New England journal of medicine,2025 09,10.1056/NEJMc2511029,,Correspondence
40961440,Navigating the Discontinuity Crisis in Medical Education.,"Schenkel Stephen, Gingold Daniel B, Spangler Ryan",The New England journal of medicine,2025 09,10.1056/NEJMc2511029,,Correspondence
40961439,Ondansetron after ED Visits in Children with Gastroenteritis. Reply.,"Freedman Stephen B, Klassen Terry P",The New England journal of medicine,2025 09,10.1056/NEJMc2511678,,Correspondence
40961438,Ondansetron after ED Visits in Children with Gastroenteritis.,"Niel Olivier, Caliment Ancuta",The New England journal of medicine,2025 09,10.1056/NEJMc2511678,,Correspondence
40961437,Ondansetron after ED Visits in Children with Gastroenteritis.,Wang Tingxuan,The New England journal of medicine,2025 09,10.1056/NEJMc2511678,,Correspondence
40961436,Ondansetron after ED Visits in Children with Gastroenteritis.,"Zhao Bin, Wang Chenglong, Weng Xiaojian",The New England journal of medicine,2025 09,10.1056/NEJMc2511678,,Correspondence
40961435,Perioperative Pembrolizumab in Head and Neck Cancer. Reply.,"Uppaluri Ravindra, Haddad Robert I, Adkins Douglas",The New England journal of medicine,2025 09,10.1056/NEJMc2510882,,Correspondence
40961434,Perioperative Pembrolizumab in Head and Neck Cancer.,Desai Parth,The New England journal of medicine,2025 09,10.1056/NEJMc2510882,,Correspondence
40961433,Perioperative Pembrolizumab in Head and Neck Cancer.,Suto Hirotaka,The New England journal of medicine,2025 09,10.1056/NEJMc2510882,,Correspondence
40961432,Introduction of Mpox Virus Clade Ib into the Republic of the Congo.,"Koukouikila-Koussounda F&#xe9;lix, Yinda Claude Kwe, Mayengue Pembe I, Elenga Reiche G, Boussam Dachel A E",The New England journal of medicine,2025 09,10.1056/NEJMc2504089,,Correspondence
40961426,Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer.,"Martling Anna, Hed Myrberg Ida, Nilbert Mef, Gr&#xf6;nberg Henrik, Granath Fredrik",The New England journal of medicine,2025 09,10.1056/NEJMoa2504650,"Aspirin reduces the incidence of colorectal adenoma and colorectal cancer among high-risk persons. Observational studies suggest that aspirin may also improve disease-free survival after diagnosis, particularly among patients with tumors harboring somatic PIK3CA mutations. However, data from randomized trials are lacking.",Correspondence
40961423,Clesrovimab in Infants and Children at Increased Risk for Severe RSV Disease.,"Zar Heather J, Bont Louis J, Manzoni Paolo, Mu&#xf1;oz Flor M, Ramilo Octavio",The New England journal of medicine,2025 10,10.1056/NEJMc2506107,,Correspondence
40961420,In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus.,"Wang Qian, Xiao Ze Xiu, Zheng Xu, Wang Guihong, Yang Linlin",The New England journal of medicine,2025 10,10.1056/NEJMc2509522,,Correspondence
40960253,A Randomized Trial of Shunting for Idiopathic Normal-Pressure Hydrocephalus.,"Luciano Mark G, Williams Michael A, Hamilton Mark G, Katzen Heather L, Dasher Nickolas A",The New England journal of medicine,2025 12,10.1056/NEJMoa2503109,"Idiopathic normal-pressure hydrocephalus is a neurologic disorder characterized by impaired gait, balance, cognition, and bladder control in older adults. The disorder is treated with shunt surgery, but the effectiveness of shunting is unclear.",Correspondence
40960239,"Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.","Wharton Sean, Aronne Louis J, Stefanski Adam, Alfaris Nasreen F, Ciudin Andreea",The New England journal of medicine,2025 11,10.1056/NEJMoa2511774,"Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity.",Original Article
40934115,Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.,"Wharton Sean, Lingvay Ildiko, Bogdanski Pawel, Duque do Vale Ruben, Jacob Stephan",The New England journal of medicine,2025 09,10.1056/NEJMoa2500969,Oral semaglutide at a dose of 25 mg may provide an alternative treatment option to injectable semaglutide (2.4 mg) and higher-dose oral semaglutide (50 mg) for persons with overweight or obesity.,Correspondence
40929642,Once-Weekly Mazdutide in Obesity or Overweight. Reply.,"Ji Linong, Qian Lei",The New England journal of medicine,2025 09,10.1056/NEJMc2509841,,Correspondence
40929641,Once-Weekly Mazdutide in Obesity or Overweight.,"Zhang Yan, Yu Lei, Liu Zhen-Tong",The New England journal of medicine,2025 09,10.1056/NEJMc2509841,,Correspondence
40929640,Efruxifermin in Compensated Liver Cirrhosis Caused by MASH. Reply.,"Noureddin Mazen, Shringarpure Reshma, Yale Kitty",The New England journal of medicine,2025 09,10.1056/NEJMc2510444,,Correspondence
40929639,Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.,Yu Linghua,The New England journal of medicine,2025 09,10.1056/NEJMc2510444,,Correspondence
40929634,Medications for Opioid Use Disorder in County Jails - Outcomes after Release.,"Friedmann Peter D, Wilson Donna, Stopka Thomas J, Bernson Dana, Pivovarova Ekaterina",The New England journal of medicine,2025 09,10.1056/NEJMsa2415987,"In 2019, seven county correctional facilities (jails) in Massachusetts initiated pilot programs to provide all Food and Drug Administration-approved medications for opioid use disorder (MOUD).",Correspondence
40929633,"Marburg Virus Disease in Rwanda, 2024 - Public Health and Clinical Responses.","Nsanzimana Sabin, Remera Eric, Nkeshimana Menelas, Westergaard Ryan P, Firew Tsion",The New England journal of medicine,2025 09,10.1056/NEJMoa2415816,"On September 27, 2024, Rwanda reported an outbreak of Marburg virus disease (MVD), after a cluster of cases of viral hemorrhagic fever was detected at two urban hospitals.",Correspondence
40923797,Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.,"Yang James Chih-Hsin, Lu Shun, Hayashi Hidetoshi, Felip Enriqueta, Spira Alexander I",The New England journal of medicine,2025 10,10.1056/NEJMoa2503001,Previous results from this phase 3 trial showed that progression-free survival among participants with previously untreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC) was significantly improved with amivantamab-lazertinib as compared with osimertinib. Results of the protocol-specified final overall survival analysis in this trial have not been reported.,Original Article
40902187,Generative AI in Medicine. Reply.,Maddox Thomas M,The New England journal of medicine,2025 09,10.1056/NEJMc2510443,,Correspondence
40902186,Generative AI in Medicine.,Richie Cristina S,The New England journal of medicine,2025 09,10.1056/NEJMc2510443,,Correspondence
40902185,Generative AI in Medicine.,"Chen Shanquan, Yu Jiazhou",The New England journal of medicine,2025 09,10.1056/NEJMc2510443,,Correspondence
40902184,Generative AI in Medicine.,"Kameda Yusuke, Kaneko Yutaka, Takada Saki",The New England journal of medicine,2025 09,10.1056/NEJMc2510443,,Correspondence
40902183,Malnutrition in Older Adults. Reply.,"Cruz-Jentoft Alfonso J, Volkert Dorothee",The New England journal of medicine,2025 09,10.1056/NEJMc2509709,,Correspondence
40902182,Malnutrition in Older Adults.,"Zhang Bo, Zhang Haijun",The New England journal of medicine,2025 09,10.1056/NEJMc2509709,,Correspondence
40902181,Malnutrition in Older Adults.,"Du Heyue, Atkins Michael, Joyner Robert",The New England journal of medicine,2025 09,10.1056/NEJMc2509709,,Correspondence
40902180,Malnutrition in Older Adults.,"Minichmayr Iris K, Zeitlinger Markus",The New England journal of medicine,2025 09,10.1056/NEJMc2509709,,Correspondence
40902179,Porcine Xenotransplantation in End-Stage Kidney Disease. Reply.,"Kawai Tatsuo, Riella Leonard V",The New England journal of medicine,2025 09,10.1056/NEJMc2508235,,Correspondence
40902178,Porcine Xenotransplantation in End-Stage Kidney Disease.,"Melilli Edoardo, Garcia Romero Elena",The New England journal of medicine,2025 09,10.1056/NEJMc2508235,,Correspondence
40902177,Porcine Xenotransplantation in End-Stage Kidney Disease.,"Weinrauch Larry A, D'Elia John A",The New England journal of medicine,2025 09,10.1056/NEJMc2508235,,Correspondence
40902176,Porcine Xenotransplantation in End-Stage Kidney Disease.,"Jiang Qiqi, Ye Liefu, Wu Jinfeng",The New England journal of medicine,2025 09,10.1056/NEJMc2508235,,Correspondence
40902175,Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. Reply.,"Nicholls Stephen J, Nelson Adam J, Ray Kausik K",The New England journal of medicine,2025 09,10.1056/NEJMc2510693,,Correspondence
40902174,Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.,"Guo Mengmeng, Liu Zunjing",The New England journal of medicine,2025 09,10.1056/NEJMc2510693,,Correspondence
40902173,Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.,"Zhang Dong, Wu Hui, Gong Shengyu",The New England journal of medicine,2025 09,10.1056/NEJMc2510693,,Correspondence
40902172,Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.,Modarressi Taher,The New England journal of medicine,2025 09,10.1056/NEJMc2510693,,Correspondence
40902171,Fulminant Viral Myocarditis Associated with Thogotovirus.,"Osawa Shuichi, Miyazaki Kenji, Mine Sohtaro, Hirata Yuichiro, Terada Norihiko",The New England journal of medicine,2025 09,10.1056/NEJMc2503343,,Correspondence
40902162,Monoclonal Antibodies in the Pathogenesis of Heparin-Induced Thrombocytopenia.,"Treverton Jared, Arnold Donald M, Ivanov Daniil G, Ivetic Nikola, Zhang Yi",The New England journal of medicine,2025 09,10.1056/NEJMoa2507175,"Heparin-induced thrombocytopenia (HIT) is an immune-mediated platelet disorder caused by antibodies that target complexes of platelet factor 4 (PF4) and heparin. HIT has been characterized as a polyclonal immune response; however, studies of other rare anti-PF4 disorders have identified clonally restricted antibodies.",Correspondence
40902161,One Dose versus Three Doses of Benzathine Penicillin G in Early Syphilis.,"Hook Edward W, Dionne Jodie A, Workowski Kimberly, McNeil Candice J, Taylor Stephanie N",The New England journal of medicine,2025 09,10.1056/NEJMoa2401802,"Controversy persists regarding the appropriate duration of therapy with benzathine penicillin G in persons with early (i.e., primary, secondary, or early latent) syphilis (Treponema pallidum infection).",Correspondence
40888742,Home-Based Care for Hypertension in Rural South Africa.,"Siedner Mark J, Magula Nombulelo, Mazibuko Lusanda, Sithole Nsika, Castle Alison",The New England journal of medicine,2025 10,10.1056/NEJMoa2509958,"Poorly controlled hypertension is a common problem worldwide, particularly in low-resource settings.",Original Article
40888739,Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia.,"Bergmark Brian A, Marston Nicholas A, Prohaska Thomas A, Alexander Veronica J, Zimerman Andre",The New England journal of medicine,2025 10,10.1056/NEJMoa2507227,"Highly effective therapies to reduce triglyceride levels are lacking. Olezarsen is an N-acetylgalactosamine-conjugated antisense oligonucleotide that targets the messenger RNA of apolipoprotein C-III, which inhibits triglyceride clearance.",Original Article
40888737,Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome.,"Jeppsson Anders, James Stefan, Moller Christian H, Malm Carl Johan, Dal&#xe9;n Magnus",The New England journal of medicine,2025 12,10.1056/NEJMoa2508026,"Patients benefit from antiplatelet therapy after coronary-artery bypass grafting (CABG) for an acute coronary syndrome. Whether the addition of ticagrelor to aspirin, as compared with aspirin alone, further reduces the risk of adverse cardiovascular outcomes is unclear.",Original Article
40888734,Apixaban for Extended Treatment of Provoked Venous Thromboembolism.,"Piazza Gregory, Bikdeli Behnood, Pandey Arvind K, Krishnathasan Darsiya, Khairani Candrika D",The New England journal of medicine,2025 09,10.1056/NEJMoa2509426,"The appropriate duration of anticoagulation for venous thromboembolism (VTE) in patients who have a transient provoking factor (e.g., surgery, trauma, or immobility) and concomitant enduring risk factors is uncertain.",Original Article
40888730,Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.,"Flack John M, Azizi Michel, Brown Jenifer M, Dwyer Jamie P, Fronczek Jakub",The New England journal of medicine,2025 10,10.1056/NEJMoa2507109,"Aldosterone dysregulation plays an important pathogenic role in hard-to-control hypertension. In several studies, baxdrostat, an aldosterone synthase inhibitor, reduced the seated systolic blood pressure of patients with uncontrolled or resistant hypertension.",Correspondence
40888726,Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction.,"Tarantini Giuseppe, Honton Benjamin, Paradies Valeria, Lemesle Gilles, Range Gregoire",The New England journal of medicine,2025 11,10.1056/NEJMoa2508808,An appropriate duration of dual antiplatelet therapy after percutaneous coronary intervention for acute myocardial infarction that has been treated with guideline-recommended complete revascularization and a contemporary drug-eluting stent remains unclear.,Original Article
40888725,Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.,"Lemesle Gilles, Didier Romain, Steg Philippe Gabriel, Simon Tabassome, Montalescot Gilles",The New England journal of medicine,2025 10,10.1056/NEJMoa2507532,The appropriate antithrombotic regimen for patients with chronic coronary syndrome who are at high atherothrombotic risk and receiving long-term oral anticoagulation remains unknown.,Original Article
40888723,Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes.,"Guimar&#xe3;es Patricia O, Franken Marcelo, Tavares Caio A M, Antunes Murillo O, Silveira Fabio S",The New England journal of medicine,2025 11,10.1056/NEJMoa2507980,Whether potent P2Y12 inhibitor monotherapy without aspirin initiated shortly after successful percutaneous coronary intervention (PCI) is effective and safe for patients with acute coronary syndromes is unclear.,Original Article
40888722,Long-Term Outcomes of the DanGer Shock Trial.,"M&#xf8;ller Jacob E, Beske Rasmus P, Engstr&#xf8;m Thomas, Jensen Lisette O, Eiskj&#xe6;r Hans",The New England journal of medicine,2025 12,10.1056/NEJMc2508284,,Correspondence
40888720,High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults.,"Johansen Niklas Dyrby, Modin Daniel, Loiacono Matthew M, Harris Rebecca C, Dufournet Marine",The New England journal of medicine,2025 12,10.1056/NEJMoa2509907,"High-dose inactivated influenza vaccine has been shown to provide protection against influenza that is superior to that with the standard dose. However, data from individually randomized trials on the effectiveness of the high-dose vaccine against severe outcomes are limited.",Original Article
40888717,Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.,"Desai Milind Y, Owens Anjali T, Abraham Theodore, Olivotto Iacopo, Garcia-Pavia Pablo",The New England journal of medicine,2025 09,10.1056/NEJMoa2505927,"Mavacamten is approved to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). However, its effects in nonobstructive HCM remain uncertain.",Original Article
40888716,Beta-Blockers after Myocardial Infarction in Patients without Heart Failure.,"Munkhaugen John, Kristensen Anna Meta D, Halvorsen Sigrun, Holmager Therese, Olsen Michael Hecht",The New England journal of medicine,2025 11,10.1056/NEJMoa2505985,The evidence supporting beta-blocker therapy after myocardial infarction was established before the introduction of modern coronary reperfusion therapy and secondary prevention strategies.,Original Article
40888702,Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction.,"Ibanez Borja, Latini Roberto, Rossello Xavier, Dominguez-Rodriguez Alberto, Fern&#xe1;ndez-Vazquez Felipe",The New England journal of medicine,2025 11,10.1056/NEJMoa2504735,"Current guideline recommendations for the use of beta-blockers after myocardial infarction without reduced ejection fraction are based on trials conducted before routine reperfusion, invasive care, complete revascularization, and contemporary pharmacologic therapies became standard practice.",Original Article
40888697,Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy.,"Garcia-Pavia Pablo, Maron Martin S, Masri Ahmad, Merkely Bela, Nassif Michael E",The New England journal of medicine,2025 09,10.1056/NEJMoa2504654,"Beta-blockers have been the initial treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM) despite limited evidence of their efficacy. Aficamten is a cardiac myosin inhibitor that reduces left ventricular outflow tract gradients, improves exercise capacity, and decreases HCM symptoms when added to standard medications. Whether aficamten as monotherapy provides greater clinical benefit than beta-blockers as monotherapy remains unknown.",Original Article
40888695,RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults.,"Lassen Mats C H&#xf8;jbjerg, Johansen Niklas Dyrby, Christensen Sine H, Aliabadi Negar, Skaarup Kristoffer G",The New England journal of medicine,2026 01,10.1056/NEJMoa2509810,"Respiratory syncytial virus (RSV) can cause serious illness in older adults. The bivalent RSV prefusion F protein-based vaccine (RSVpreF) has been shown to prevent RSV-associated respiratory illness, but data from randomized trials with regard to its effect on outcomes involving hospitalization are limited.",Original Article
40888694,High-Dose Influenza Vaccine to Reduce Hospitalizations.,"Pardo-Seco Jacobo, Rodr&#xed;guez-Tenreiro-S&#xe1;nchez Carmen, Gin&#xe9;-V&#xe1;zquez Iago, Mallah Narmeen, Mir&#xe1;s-Carballal Susana",The New England journal of medicine,2025 12,10.1056/NEJMoa2509834,"Superior protection against laboratory-confirmed influenza has been proved for high-dose inactivated influenza vaccine, as compared with the standard dose, among adults 65 years of age or older. However, data on the relative effectiveness of the high-dose vaccine against severe clinical outcomes, including hospitalizations, are limited.",Original Article
40879434,Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.,"Bavendiek Udo, Gro&#xdf;hennig Anika, Schwab Johannes, Berliner Dominik, Rieth Andreas",The New England journal of medicine,2025 09,10.1056/NEJMoa2415471,The therapeutic efficacy of the cardiac glycoside digitoxin in patients with heart failure and reduced ejection fraction is not established.,Original Article
40879431,Multidomain Rehabilitation for Older Patients with Myocardial Infarction.,"Tonet Elisabetta, Raisi Andrea, Zagnoni Silvia, Chiaranda Giorgio, Pasanisi Giovanni",The New England journal of medicine,2025 09,10.1056/NEJMoa2502799,The benefit of rehabilitation interventions in patients who are 65 years of age or older with myocardial infarction and impaired physical performance remains unclear.,Original Article
40879429,Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias.,"J&#xf8;ns Christian, Zheng Chaoqun, Winsl&#xf8;w Ulrik C G, Danielsen Elisabeth M, Sakthivel Tharsika",The New England journal of medicine,2025 11,10.1056/NEJMoa2509542,Hypokalemia and even low-normal plasma potassium levels increase the risk of ventricular arrhythmias among patients with cardiovascular disease. An assessment of a strategy of actively increasing plasma potassium levels to the high-normal range is needed.,Original Article
40879421,Reduction of Antihypertensive Treatment in Nursing Home Residents.,"Benetos Athanase, Gautier Sylvie, Freminet Anne, Metz Alice, Labat Carlos",The New England journal of medicine,2025 11,10.1056/NEJMoa2508157,"Among older adults with frailty, evidence on the benefits and risks of discontinuing antihypertensive drugs is limited.",Original Article
40834319,Screening for Prostate Cancer with a Polygenic Risk Score. Reply.,"Bancroft Elizabeth K, McHugh Jana K, Eeles Rosalind A",The New England journal of medicine,2025 09,10.1056/NEJMc2507786,,Correspondence
40834318,Screening for Prostate Cancer with a Polygenic Risk Score.,"Green Harry D, Jackson Leigh, Bailey Sarah E R",The New England journal of medicine,2025 09,10.1056/NEJMc2507786,,Correspondence
40834317,Screening for Prostate Cancer with a Polygenic Risk Score.,"Su Chen-Yang, Hasebe Masashi",The New England journal of medicine,2025 09,10.1056/NEJMc2507786,,Correspondence
40834316,Screening for Prostate Cancer with a Polygenic Risk Score.,"Eklund Martin, Thompson Ian M, Cooperberg Matthew R",The New England journal of medicine,2025 09,10.1056/NEJMc2507786,,Correspondence
40834315,AAV Gene Therapy in Severe Hemophilia B. Reply.,"Reiss Ulrike M, Davidoff Andrew M, Nathwani Amit C",The New England journal of medicine,2025 09,10.1056/NEJMc2509703,,Correspondence
40834314,AAV Gene Therapy in Severe Hemophilia B.,"Miesbach Wolfgang, Peyvandi Flora, Pierce Glenn F",The New England journal of medicine,2025 09,10.1056/NEJMc2509703,,Correspondence
40834313,Omitting Nodal Irradiation after Nodes Clear.,"Braunstein Lior Z, Morrow Monica",The New England journal of medicine,2025 09,10.1056/NEJMc2509175,,Correspondence
40834312,Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. Reply.,"Sanyal Arun J, Newsome Philip N",The New England journal of medicine,2025 09,10.1056/NEJMc2509454,,Correspondence
40834311,Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.,"Su Chen-Yang, Hasebe Masashi",The New England journal of medicine,2025 09,10.1056/NEJMc2509454,,Correspondence
40834310,Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.,"Rivera-Esteban Jesus, Valverde-Salazar V&#xed;ctor, Calleja Jos&#xe9; L",The New England journal of medicine,2025 09,10.1056/NEJMc2509454,,Correspondence
40834309,Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.,"Lavender James, Bollipo Steven, Talley Nicholas",The New England journal of medicine,2025 09,10.1056/NEJMc2509454,,Correspondence
40834308,Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.,"Luo Susu, Liu Hui, Jin Wenyi",The New England journal of medicine,2025 09,10.1056/NEJMc2509454,,Correspondence
40834307,Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy.,"Aleman Adolfo, Van Oekelen Oliver, Melnekoff David T, Grossman Leah, Mouhieddine Tarek H",The New England journal of medicine,2025 09,10.1056/NEJMc2504588,,Correspondence
40834301,Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis.,"Trapnell Bruce C, Inoue Yoshikazu, Bonella Francesco, Wang Tisha, McCarthy Cormac",The New England journal of medicine,2025 08,10.1056/NEJMoa2410542,"Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare disease characterized by progressive surfactant accumulation and hypoxemia caused by autoantibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF), which alveolar macrophages require to clear surfactant. Molgramostim is a formulation of inhaled recombinant human GM-CSF, but its efficacy and safety in patients with aPAP have not been studied sufficiently.",Original Article
40802959,Cancer of Unknown Primary Site. Reply.,Raghav Kanwal,The New England journal of medicine,2025 09,10.1056/NEJMc2508962,,Correspondence
40802958,Cancer of Unknown Primary Site.,"Bellanti Joseph A, Li Dongmei",The New England journal of medicine,2025 09,10.1056/NEJMc2508962,,Correspondence
40802957,Cancer of Unknown Primary Site.,Bibas Michele,The New England journal of medicine,2025 09,10.1056/NEJMc2508962,,Correspondence
40802956,Lorundrostat Efficacy and Safety in Uncontrolled Hypertension. Reply.,"Laffin Luke J, Rodman David, Nissen Steven E",The New England journal of medicine,2025 09,10.1056/NEJMc2507996,,Correspondence
40802955,Lorundrostat Efficacy and Safety in Uncontrolled Hypertension.,Pollock James M,The New England journal of medicine,2025 09,10.1056/NEJMc2507996,,Correspondence
40802954,Lorundrostat Efficacy and Safety in Uncontrolled Hypertension.,"Burgos Elena, Fern&#xe1;ndez Fern&#xe1;ndez Beatriz, Ortiz Alberto",The New England journal of medicine,2025 09,10.1056/NEJMc2507996,,Correspondence
40802953,Oral Semaglutide and Cardiovascular Outcomes. Reply.,"McGuire Darren K, David Jens-Peter, Inzucchi Silvio E",The New England journal of medicine,2025 09,10.1056/NEJMc2508958,,Correspondence
40802952,Oral Semaglutide and Cardiovascular Outcomes.,"Dos Santos Marcel Cat&#xe3;o F, de Lima Nat&#xe1;lia N&#xf3;brega, Lima Josivan G",The New England journal of medicine,2025 09,10.1056/NEJMc2508958,,Correspondence
40802951,A Naturally Occurring Gain-of-Function Mutation in Factor VIII.,"Wischmeyer Joshua T, Baird Christine H, Grandvallet Contreras Julian, Tran Alexander, Phang Tzu",The New England journal of medicine,2025 09,10.1056/NEJMc2507228,,Correspondence
40802943,Risdiplam in Presymptomatic Spinal Muscular Atrophy.,"Finkel Richard S, Servais Laurent, Vlodavets Dmitry, Zanoteli Edmar, Mazurkiewicz-Be&#x142;dzi&#x144;ska Maria",The New England journal of medicine,2025 08,10.1056/NEJMoa2410120,"Risdiplam, an oral pre-messenger RNA splicing modifier, is an efficacious treatment for persons with symptomatic spinal muscular atrophy (SMA). The safety and efficacy of risdiplam in presymptomatic disease are unclear.",Original Article
40768736,Neonatal Fc Receptor - Biology and Therapeutics. Reply.,"Bussel James B, Cines Douglas B, Blumberg Richard S",The New England journal of medicine,2025 09,10.1056/NEJMc2507104,,Correspondence
40768735,Neonatal Fc Receptor - Biology and Therapeutics.,"Li Haoxian, Wu Yong",The New England journal of medicine,2025 09,10.1056/NEJMc2507104,,Correspondence
40768734,Neonatal Fc Receptor - Biology and Therapeutics.,Misbah Siraj A,The New England journal of medicine,2025 09,10.1056/NEJMc2507104,,Correspondence
40768733,Malaria. Reply.,"Daily Johanna P, Parikh Sunil",The New England journal of medicine,2025 09,10.1056/NEJMc2507763,,Correspondence
40768732,Malaria.,"Barkati Sapha, Balerdi-Sarasola Leire, Yansouni C&#xe9;dric P",The New England journal of medicine,2025 09,10.1056/NEJMc2507763,,Correspondence
40768731,Enhanced CAR T-Cell Therapy for Relapsed Lymphoma. Reply.,"Svoboda Jakub, Hexner Elizabeth, June Carl H",The New England journal of medicine,2025 09,10.1056/NEJMc2507794,,Correspondence
40768730,Enhanced CAR T-Cell Therapy for Relapsed Lymphoma.,"Vairamoorthy Naveen, Kazi Bilal, Patil Vijay",The New England journal of medicine,2025 09,10.1056/NEJMc2507794,,Correspondence
40768729,A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes. Reply.,"Kudva Yogish C, Beck Roy W",The New England journal of medicine,2025 09,10.1056/NEJMc2507995,,Correspondence
40768728,A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes.,"Zhang Fan, Zhong Yifei",The New England journal of medicine,2025 09,10.1056/NEJMc2507995,,Correspondence
40768727,A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes.,Saxon David,The New England journal of medicine,2025 09,10.1056/NEJMc2507995,,Correspondence
40768726,Daratumumab for High-Risk Smoldering Multiple Myeloma. Reply.,"Dimopoulos Meletios A, Voorhees Peter M, Rajkumar S Vincent",The New England journal of medicine,2025 09,10.1056/NEJMc2507790,,Correspondence
40768725,Daratumumab for High-Risk Smoldering Multiple Myeloma.,"Shanmugam Surish P, Awwad Aya",The New England journal of medicine,2025 09,10.1056/NEJMc2507790,,Correspondence
40768724,Xenon - Propelling Climbers to the Summits of the World's Highest Mountains?,Burtscher Martin,The New England journal of medicine,2025 09,10.1056/NEJMc2507671,,Correspondence
40768716,Ciprofloxacin versus Aminoglycoside-Ciprofloxacin for Bubonic Plague.,"Randremanana Rindra Vatosoa, Raberahona Mihaja, Bourner Josephine, Rajerison Minoarisoa, Edwards Tansy",The New England journal of medicine,2025 08,10.1056/NEJMoa2413772,Plague is a high-consequence infectious disease with epidemic potential. Current treatment guidelines are based on weak evidence.,Correspondence
40757665,Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression.,"Carlsson Per-Ola, Hu Xiaomeng, Scholz Hanne, Ingvast Sofie, Lundgren Torbj&#xf6;rn",The New England journal of medicine,2025 09,10.1056/NEJMoa2503822,The need to suppress a patient's immune system after the transplantation of allogeneic cells is associated with wide-ranging side effects. We report the outcomes of transplantation of genetically modified allogeneic donor islet cells into a man with long-standing type 1 diabetes. We used clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 12b (Cas12b) editing and lentiviral transduction to genetically edit the cells to avoid rejection; the cells were then...,Correspondence
40742269,Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation. Reply.,"Reichlin Tobias, J&#xfc;ni Peter, Sticherling Christian",The New England journal of medicine,2025 09,10.1056/NEJMc2506666,,Correspondence
40742268,Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation.,"Chen Mingxian, Li Xuping, Zhou Shenghua",The New England journal of medicine,2025 09,10.1056/NEJMc2506666,,Correspondence
40742267,Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation.,"Karakasis Paschalis, Fragakis Nikolaos",The New England journal of medicine,2025 09,10.1056/NEJMc2506666,,Correspondence
40742266,Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation.,"Blackwell Jacob N, Wang Norman C, Bhonsale Aditya",The New England journal of medicine,2025 09,10.1056/NEJMc2506666,,Correspondence
40742260,Resolution of Squamous-Cell Carcinoma by Restoring T-Cell Receptor Signaling.,"Ye Peiying, Bergerson Jenna R E, Brownell Isaac, Starrett Gabriel J, Abraham Roshini S",The New England journal of medicine,2025 07,10.1056/NEJMoa2502114,"Cutaneous squamous-cell carcinoma (SCC) is primarily caused by oncogenesis mediated by ultraviolet radiation, and &#x3b2;-human papillomavirus (&#x3b2;-HPV) is believed to be a mere facilitator that is dispensable for the maintenance of cutaneous SCC. Here, we describe a woman with benign and malignant HPV-related diseases that include a recurrent, unresectable, invasive cutaneous SCC with &#x3b2;-HPV19 genomic integration in the context of germline pathogenic mutations in ZAP70, an adapter requ...",Correspondence
40700709,Enteral Nutrition in Hospitalized Adults. Reply.,"Gramlich Leah, Guenter Peggi",The New England journal of medicine,2025 09,10.1056/NEJMc2506662,,Correspondence
40700708,Enteral Nutrition in Hospitalized Adults.,"Tripoloni Daniel E, Canaro Garc&#xed;a Mercedes, Gall Juana",The New England journal of medicine,2025 09,10.1056/NEJMc2506662,,Correspondence
40700707,Enteral Nutrition in Hospitalized Adults.,Finucane Thomas E,The New England journal of medicine,2025 09,10.1056/NEJMc2506662,,Correspondence
40700706,Evolving Epidemiology of Mpox in Africa in 2024. Reply.,"Ndembi Nicaise, Folayan Morenike O, Abdool Karim Salim S",The New England journal of medicine,2025 09,10.1056/NEJMc2503635,,Correspondence
40700705,Evolving Epidemiology of Mpox in Africa in 2024.,"Preiser Wolfgang, Weyer Jacqueline, Moyo Sikhulile",The New England journal of medicine,2025 09,10.1056/NEJMc2503635,,Correspondence
40700704,BCG Revaccination to Prevent Tuberculosis. Reply.,"Schmidt Alexander C, Nemes Elisa, Hatherill Mark",The New England journal of medicine,2025 09,10.1056/NEJMc2507859,,Correspondence
40700703,BCG Revaccination to Prevent Tuberculosis.,Singh Urvashi B,The New England journal of medicine,2025 09,10.1056/NEJMc2507859,,Correspondence
40700702,BCG Revaccination to Prevent Tuberculosis.,"Joshi Manish, Bartter Thaddeus, Joshi Anita",The New England journal of medicine,2025 09,10.1056/NEJMc2507859,,Correspondence
40700701,Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a). Reply.,"Nissen Steven E, Navar Ann Marie, Krege John H",The New England journal of medicine,2025 09,10.1056/NEJMc2507989,,Correspondence
40700700,Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a).,Higashi Yukihito,The New England journal of medicine,2025 09,10.1056/NEJMc2507989,,Correspondence
40700699,Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. Reply.,"Furie Richard A, Rovin Brad H, Pendergraft William F",The New England journal of medicine,2025 09,10.1056/NEJMc2506672,,Correspondence
40700698,Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.,"de Fr&#xe9;mont Gr&#xe9;goire Martin, Le Guern V&#xe9;ronique, Costedoat-Chalumeau Nathalie",The New England journal of medicine,2025 09,10.1056/NEJMc2506672,,Correspondence
40700697,Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.,Karassa Fotini B,The New England journal of medicine,2025 09,10.1056/NEJMc2506672,,Correspondence
40700696,Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.,Sahutoglu Tuncay,The New England journal of medicine,2025 09,10.1056/NEJMc2506672,,Correspondence
40700695,Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.,"Angeletti Andrea, Maras&#xe0; Maddalena, Cravedi Paolo",The New England journal of medicine,2025 09,10.1056/NEJMc2506672,,Correspondence
40700688,Ivermectin to Control Malaria - A Cluster-Randomized Trial.,"Chaccour Carlos, Maia Marta, Kariuki Mercy, Ruiz-Castillo Paula, Wanjiku Caroline",The New England journal of medicine,2025 07,10.1056/NEJMoa2411262,"Malaria control and elimination is threatened by the spread of insecticide resistance and behavioral adaptation of vectors. Whether mass administration of ivermectin, a broad-spectrum antiparasitic drug that also kills mosquitoes feeding on treated persons, can reduce malaria transmission is unclear.",Original Article
40689593,Mitochondrial Donation in a Reproductive Care Pathway for mtDNA Disease.,"McFarland Robert, Hyslop Louise A, Feeney Catherine, Pillai Rekha N, Blakely Emma L",The New England journal of medicine,2025 07,10.1056/NEJMoa2503658,"Pathogenic variants in mitochondrial DNA (mtDNA) are a common cause of severe, often fatal, inherited metabolic disease. A reproductive care pathway was implemented to provide women carrying pathogenic mtDNA variants with reproductive options. A total of 22 women with pathogenic mtDNA variants have commenced or completed pronuclear transfer (and thus receipt of a mitochondrial donation), and there have been 8 live births. All 8 children were healthy at birth, with no or low levels of mtDNA heter...",Original Article
40673696,Mitochondrial Donation and Preimplantation Genetic Testing for mtDNA Disease.,"Hyslop Louise A, Blakely Emma L, Aushev Magomet, Marley Jordan, Takeda Yuko",The New England journal of medicine,2025 07,10.1056/NEJMoa2415539,"Children born to women who carry pathogenic variants in mitochondrial DNA (mtDNA) are at risk for a range of clinical syndromes collectively known as mtDNA disease. Mitochondrial donation by pronuclear transfer involves transplantation of nuclear genome from a fertilized egg from the affected woman to an enucleated fertilized egg donated by an unaffected woman. Thus, pronuclear transfer offers affected women the potential to have a genetically related child with a reduced risk of mtDNA disease.",Correspondence
40673596,Apixaban for Cancer-Associated Venous Thromboembolism. Reply.,"Mah&#xe9; Isabelle, Carrier Marc, Laporte Silvy",The New England journal of medicine,2025 09,10.1056/NEJMc2506526,,Correspondence
40673595,Apixaban for Cancer-Associated Venous Thromboembolism.,"Conteduca Vincenza, Giordano Guido, Landriscina Matteo",The New England journal of medicine,2025 09,10.1056/NEJMc2506526,,Correspondence
40673594,Apixaban for Cancer-Associated Venous Thromboembolism.,"Ding Yong Jie, Huang Ke, Li Qing Yun",The New England journal of medicine,2025 09,10.1056/NEJMc2506526,,Correspondence
40673593,Apixaban for Cancer-Associated Venous Thromboembolism.,"Wu Gujie, Liu Weiwei, Sheung Lee",The New England journal of medicine,2025 09,10.1056/NEJMc2506526,,Correspondence
40673592,Apixaban for Cancer-Associated Venous Thromboembolism.,"Shao Zhuo, Zhai Xinyu",The New England journal of medicine,2025 09,10.1056/NEJMc2506526,,Correspondence
40673591,Monoclonal Anti-Platelet Factor 4 Antibodies in Recurrent Pregnancy Loss.,"Bavli Natalie R, Kanack Adam J, Nishimura Yoshito, Splinter Noah P, Mauch Emily E",The New England journal of medicine,2025 09,10.1056/NEJMc2506014,,Correspondence
40673586,On-Table Reanimation of a Pediatric Heart from Donation after Circulatory Death.,"Kucera John A, Overbey Douglas M, Turek Joseph W",The New England journal of medicine,2025 07,10.1056/NEJMoa2503487,"Cardiac allotransplantation is warranted in children with end-stage heart failure or irreparable congenital heart disease. A dearth of organs for transplantation has contributed to long wait-list times and resultant deaths in this population. Donation after circulatory death (DCD) with normothermic regional perfusion has the potential to increase the donor pool by up to 30%. Ethical concerns have limited adoption of this technique in the United States and abroad. Consequently, a method facilitat...",Original Article
40673585,Rapid Recovery of Donor Hearts for Transplantation after Circulatory Death.,"Williams Aaron M, Trahanas John M, Bommareddi Swaroop, Lima Brian, DeVries Stephen A",The New England journal of medicine,2025 07,10.1056/NEJMoa2500456,"We report a method for the recovery of hearts for transplantation from deceased donors after circulatory death that obviates the need for thoracoabdominal normothermic regional perfusion or ex situ perfusion systems. After death, the aorta is clamped and a flush circuit is established to perform a controlled, extended, ultraoxygenated flush of the donor heart at a mean aortic-root pressure of 80 mm Hg. In the first three reported cases in which this method was used, the hearts were transplanted ...",Original Article
40673584,Multidose Ondansetron after Emergency Visits in Children with Gastroenteritis.,"Freedman Stephen B, Williamson-Urquhart Sarah, Plint Amy C, Dixon Andrew, Beer Darcy",The New England journal of medicine,2025 07,10.1056/NEJMoa2503596,"Ondansetron improves outcomes when administered in emergency departments to children with acute gastroenteritis-associated vomiting. It is commonly prescribed at discharge to reduce symptoms, but evidence to support this practice is limited.",Correspondence
40658651,Phase 2a Study of Baxdrostat in Primary Aldosteronism.,"Turcu Adina F, Freeman Mason W, Bancos Irina, Ben-Shlomo Anat, Hamidi Oksana",The New England journal of medicine,2025 10,10.1056/NEJMc2508629,,Correspondence
40632988,An Evidence-Based Approach to Covid-19 Vaccination. Reply.,"Prasad Vinay, Makary Martin A",The New England journal of medicine,2025 07,10.1056/NEJMc2507760,,Correspondence
40632987,An Evidence-Based Approach to Covid-19 Vaccination.,Meyerowitz Eric A,The New England journal of medicine,2025 07,10.1056/NEJMc2507760,,Correspondence
40632986,An Evidence-Based Approach to Covid-19 Vaccination.,Drekonja Dimitri,The New England journal of medicine,2025 07,10.1056/NEJMc2507760,,Correspondence
40632985,An Evidence-Based Approach to Covid-19 Vaccination.,"Vohra-Miller Sabina, Marnik Elisabeth A",The New England journal of medicine,2025 07,10.1056/NEJMc2507760,,Correspondence
40632984,An Evidence-Based Approach to Covid-19 Vaccination.,"Haidar Ghady, Hauschildt Katrina E, Michaels Marian G",The New England journal of medicine,2025 07,10.1056/NEJMc2507760,,Correspondence
40632983,An Evidence-Based Approach to Covid-19 Vaccination.,Pappas Georgios,The New England journal of medicine,2025 07,10.1056/NEJMc2507760,,Correspondence
40632970,Addressing Alcohol Use. Reply.,"Bradley Katharine A, Krist Alex H",The New England journal of medicine,2025 09,10.1056/NEJMc2507457,,Correspondence
40632969,Addressing Alcohol Use.,"V&#xe1;zquez-Ruiz Zenaida, Mart&#xed;nez-Gonz&#xe1;lez Miguel A",The New England journal of medicine,2025 09,10.1056/NEJMc2507457,,Correspondence
40632968,Wealth and Mortality in the United States and Europe. Reply.,"Papanicolas Irene, Machado Sara, Kyriopoulos Ilias",The New England journal of medicine,2025 09,10.1056/NEJMc2506058,,Correspondence
40632967,Wealth and Mortality in the United States and Europe.,Bellumkonda Lavanya,The New England journal of medicine,2025 09,10.1056/NEJMc2506058,,Correspondence
40632966,Wealth and Mortality in the United States and Europe.,"Corrales-Medina Vicente F, Cameron D William",The New England journal of medicine,2025 09,10.1056/NEJMc2506058,,Correspondence
40632965,Wealth and Mortality in the United States and Europe.,Zhao Jie V,The New England journal of medicine,2025 09,10.1056/NEJMc2506058,,Correspondence
40632964,Tumor-Infiltrating Clonal Hematopoiesis. Reply.,"Bernard Elsa, Pich Oriol, Swanton Charles",The New England journal of medicine,2025 09,10.1056/NEJMc2507106,,Correspondence
40632963,Tumor-Infiltrating Clonal Hematopoiesis.,"Spetzler David, Antonarakis Emmanuel S, Sledge George",The New England journal of medicine,2025 09,10.1056/NEJMc2507106,,Correspondence
40632962,Atrial Appendage Closure after Ablation for Atrial Fibrillation. Reply.,"Wazni Oussama M, Roy Kristine",The New England journal of medicine,2025 09,10.1056/NEJMc2506060,,Correspondence
40632961,Atrial Appendage Closure after Ablation for Atrial Fibrillation.,Leon-Acuna Isaac G,The New England journal of medicine,2025 09,10.1056/NEJMc2506060,,Correspondence
40632960,Atrial Appendage Closure after Ablation for Atrial Fibrillation.,Pimentel Maur&#xed;cio,The New England journal of medicine,2025 09,10.1056/NEJMc2506060,,Correspondence
40632959,Atrial Appendage Closure after Ablation for Atrial Fibrillation.,"Occhipinti Giovanni, Brugaletta Salvatore, Sabat&#xe9; Manel",The New England journal of medicine,2025 09,10.1056/NEJMc2506060,,Correspondence
40632958,Atrial Appendage Closure after Ablation for Atrial Fibrillation.,Byun Jae Hyun,The New England journal of medicine,2025 09,10.1056/NEJMc2506060,,Correspondence
40632957,Atrial Appendage Closure after Ablation for Atrial Fibrillation.,"Tam Mark T K, Chan Joseph Y S, So Kent C Y",The New England journal of medicine,2025 09,10.1056/NEJMc2506060,,Correspondence
40632956,"Expansion of tetM-Carrying Neisseria gonorrhoeae in the United States, 2018-2024.","Helekal David, Mortimer Tatum D, Grad Yonatan H",The New England journal of medicine,2025 09,10.1056/NEJMc2504010,,Correspondence
40616232,Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke.,"Tao Chunrong, Liu Tianlong, Cui Tao, Liu Jie, Li Zongliang",The New England journal of medicine,2025 09,10.1056/NEJMoa2503678,"Intravenous thrombolysis remains a standard treatment for acute ischemic stroke within 4.5 hours after onset. Vascular reocclusion may occur after intravenous thrombolysis and may be preventable with an antiplatelet agent within the first 24 hours after thrombolysis. Tirofiban, a platelet glycoprotein IIb-IIIa receptor antagonist, has reduced macrovascular reocclusion in experimental models.",Original Article
40601960,Further Comments on Risdiplam for Prenatal Therapy of Spinal Muscular Atrophy. Reply.,"Finkel Richard S, Mueller Lutz, Kletzl Heidemarie",The New England journal of medicine,2025 09,10.1056/NEJMc2504911,,Correspondence
40601959,Further Comments on Risdiplam for Prenatal Therapy of Spinal Muscular Atrophy.,"Yeo Crystal J J, De Vivo Darryl C, Darras Basil T",The New England journal of medicine,2025 09,10.1056/NEJMc2504911,,Correspondence
40601958,Further Comments on Risdiplam for Prenatal Therapy of Spinal Muscular Atrophy.,"Wadman Renske I, Groen Ewout J N, van der Pol W Ludo",The New England journal of medicine,2025 09,10.1056/NEJMc2504911,,Correspondence
40601957,Dapagliflozin in Patients Undergoing TAVI. Reply.,"Raposeiras-Roub&#xed;n Sergio, Rossello Xavier, Ib&#xe1;&#xf1;ez Borja",The New England journal of medicine,2025 09,10.1056/NEJMc2506348,,Correspondence
40601956,Dapagliflozin in Patients Undergoing TAVI.,"Gus Miguel, Gus Andr&#xe9; Sant'Anna",The New England journal of medicine,2025 09,10.1056/NEJMc2506348,,Correspondence
40601955,Dapagliflozin in Patients Undergoing TAVI.,"Patoulias Dimitrios, Karakasis Paschalis, Fragakis Nikolaos",The New England journal of medicine,2025 09,10.1056/NEJMc2506348,,Correspondence
40601954,Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections. Reply.,"Daneman Nick, Fowler Robert A",The New England journal of medicine,2025 09,10.1056/NEJMc2506050,,Correspondence
40601953,Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections.,Patamatamkul Samadhi,The New England journal of medicine,2025 09,10.1056/NEJMc2506050,,Correspondence
40601952,Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections.,"Vacheron Charles-Herv&#xe9;, Taccone Fabio Silvio",The New England journal of medicine,2025 09,10.1056/NEJMc2506050,,Correspondence
40601951,Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections.,Non Lemuel R,The New England journal of medicine,2025 09,10.1056/NEJMc2506050,,Correspondence
40601950,Intensive Blood-Pressure Control in Patients with Type 2 Diabetes. Reply.,"Bi Yufang, Xu Yu, Wang Weiqing",The New England journal of medicine,2025 09,10.1056/NEJMc2506053,,Correspondence
40601949,Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.,"Grossman Ehud, Messerli Franz H",The New England journal of medicine,2025 09,10.1056/NEJMc2506053,,Correspondence
40601948,Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.,"Fernandez-Fernandez Beatriz, Sarafidis Pantelis, Ortiz Alberto",The New England journal of medicine,2025 09,10.1056/NEJMc2506053,,Correspondence
40601947,Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.,Jolobe Oscar M P,The New England journal of medicine,2025 09,10.1056/NEJMc2506053,,Correspondence
40601946,Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.,Schmieder Roland E,The New England journal of medicine,2025 09,10.1056/NEJMc2506053,,Correspondence
40601945,Lifesaving Diagnosis through Prenatal Genomic Sequencing.,"Fennell Andrew P, Roscioli Tony, Buckley Michael, Horton Ari E, Long Sarah",The New England journal of medicine,2025 09,10.1056/NEJMc2506080,,Correspondence
40561551,Case 6-2025: A 62-Year-Old Man with Abdominal Pain. Reply.,"Bromberg Gabrielle, Goodarzi Katayoon",The New England journal of medicine,2025 09,10.1056/NEJMc2504709,,Correspondence
40561550,Case 6-2025: A 62-Year-Old Man with Abdominal Pain.,Marinella Mark A,The New England journal of medicine,2025 09,10.1056/NEJMc2504709,,Correspondence
40561549,Infertility Evaluation and Treatment. Reply.,"Santoro Nanette, Polotsky Alex J",The New England journal of medicine,2025 09,10.1056/NEJMc2504905,,Correspondence
40561548,Infertility Evaluation and Treatment.,"Chen Chung-Jen, Chuang Hui-Yu, Tsai Eing-Mei",The New England journal of medicine,2025 09,10.1056/NEJMc2504905,,Correspondence
40561547,Incidence of Scrub Typhus in Rural South India. Reply.,"Devamani Carol, Alexander Neal, Schmidt Wolf-Peter",The New England journal of medicine,2025 09,10.1056/NEJMc2505251,,Correspondence
40561546,Incidence of Scrub Typhus in Rural South India.,"Mohapatra Prasata Raghab, Behera Bijayani, Mishra Baijayantimala",The New England journal of medicine,2025 09,10.1056/NEJMc2505251,,Correspondence
40561545,Tirzepatide for Obesity Treatment and Diabetes Prevention. Reply.,"Jastreboff Ania M, Bunck Mathijs C, Ahmad Nadia N",The New England journal of medicine,2025 09,10.1056/NEJMc2504728,,Correspondence
40561544,Tirzepatide for Obesity Treatment and Diabetes Prevention.,"Shukla Ajay Kumar, Bhavya Bhavya",The New England journal of medicine,2025 09,10.1056/NEJMc2504728,,Correspondence
40561543,Tirzepatide for Obesity Treatment and Diabetes Prevention.,"Birkenfeld Andreas L, Bergman Michael, Stefan Norbert",The New England journal of medicine,2025 09,10.1056/NEJMc2504728,,Correspondence
40561542,Catheter Ablation for Ventricular Tachycardia. Reply.,"Sapp John L, Tang Anthony S L, Wells George A",The New England journal of medicine,2025 09,10.1056/NEJMc2503856,,Correspondence
40561541,Catheter Ablation for Ventricular Tachycardia.,Leon-Acuna Isaac G,The New England journal of medicine,2025 09,10.1056/NEJMc2503856,,Correspondence
40561540,Catheter Ablation for Ventricular Tachycardia.,Byun Jae Hyun,The New England journal of medicine,2025 09,10.1056/NEJMc2503856,,Correspondence
40561539,Catheter Ablation for Ventricular Tachycardia.,Rosenfeld Jonathan E,The New England journal of medicine,2025 09,10.1056/NEJMc2503856,,Correspondence
40561538,Catheter Ablation for Ventricular Tachycardia.,&#x10c;uli&#x107; Viktor,The New England journal of medicine,2025 09,10.1056/NEJMc2503856,,Correspondence
40561537,Autologous Transplantation of the Entire Bulbar Ocular Surface.,"Sarnicola Enrica, Sarnicola Caterina, Machetta Federica, Reibaldi Michele, Sarnicola Vincenzo",The New England journal of medicine,2025 09,10.1056/NEJMc2414259,,Correspondence
40561529,AAV9-Mediated Gene Therapy for Infantile-Onset Pompe's Disease.,"Ma Xiuwei, Zhuang Lu, Ma Wenhao, Li Jun, Mao Yingying",The New England journal of medicine,2025 06,10.1056/NEJMoa2407766,"Four patients with infantile-onset Pompe's disease received a single intravenous injection of an adeno-associated virus serotype 9 vector carrying codon-optimized complementary DNA encoding human acid &#x3b1;-glucosidase (GAA) (dose, 1.2&#x2009;&#xd7;&#x2009;1014 vector genomes per kilogram of body weight). One patient was withdrawn from the study and subsequently died. The other patients had improvement in cardiac outcomes and motor function over a 52-week observation period. Anti-GAA antibodie...",Original Article
40549887,Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.,"Jastreboff Ania M, Ryan Donna H, Bays Harold E, Ebeling Peter R, Mackowski Mia G",The New England journal of medicine,2025 09,10.1056/NEJMoa2504214,Maridebart cafraglutide (known as MariTide) is a long-acting peptide-antibody conjugate that combines glucagon-like peptide-1 receptor agonism and glucose-dependent insulinotropic polypeptide receptor antagonism and that is intended for the treatment of obesity.,Correspondence
40548694,Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy.,"Rosenstock Julio, Bailey Timothy, Connery Lisa, Miller Eden, Desouza Cyrus",The New England journal of medicine,2025 07,10.1056/NEJMoa2502796,"In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to fasting blood glucose levels. A fixed-dose regimen of insulin efsitora alfa (efsitora), a once-weekly basal insulin, may provide a benefit in adults with type 2 diabetes who have not received previous insulin therapy.",Original Article
40544435,"Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.","Rosenstock Julio, Hsia Stanley, Nevarez Ruiz Luis, Eyde Sarah, Cox David",The New England journal of medicine,2025 09,10.1056/NEJMoa2505669,"Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and safety of orforglipron are needed.",Correspondence
40544433,Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.,"Garvey W Timothy, Bl&#xfc;her Matthias, Osorto Contreras Cynthia Karenina, Davies Melanie J, Winning Lehmann Eva",The New England journal of medicine,2025 08,10.1056/NEJMoa2502081,"Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results in early-phase trials; the efficacy of the combination (known as CagriSema) on weight loss in persons with either overweight and coexisting conditions or obesity is unknown.",Original Article
40544432,Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.,"Davies Melanie J, Bajaj Harpreet S, Broholm Christa, Eliasen Astrid, Garvey W Timothy",The New England journal of medicine,2025 08,10.1056/NEJMoa2502082,"Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight management in adults with type 2 diabetes, including those in a subgroup who are undergoing continuous glucose monitoring.",Original Article
40544428,"Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes.","Reichman Trevor W, Markmann James F, Odorico Jon, Witkowski Piotr, Fung John J",The New England journal of medicine,2025 09,10.1056/NEJMoa2506549,Zimislecel is an allogeneic stem cell-derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed.,Original Article
40532178,Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer.,"Uppaluri Ravindra, Haddad Robert I, Tao Yungan, Le Tourneau Christophe, Lee Nancy Y",The New England journal of medicine,2025 07,10.1056/NEJMoa2415434,The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is unclear.,Original Article
40532166,Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis. Reply.,"Hesseling Anneke C, Schaaf H Simon, Purchase Susan E",The New England journal of medicine,2025 09,10.1056/NEJMc2502735,,Correspondence
40532165,Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis. Reply.,"Fox Greg J, Nhung Nguyen Viet, Marks Guy B",The New England journal of medicine,2025 09,10.1056/NEJMc2502735,,Correspondence
40532164,Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis.,Wang Mao-Shui,The New England journal of medicine,2025 09,10.1056/NEJMc2502735,,Correspondence
40532163,Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis.,Lubelchek Ronald,The New England journal of medicine,2025 09,10.1056/NEJMc2502735,,Correspondence
40532162,Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis.,Malozowski Saul,The New England journal of medicine,2025 09,10.1056/NEJMc2502735,,Correspondence
40532161,Oral Infigratinib Therapy in Children with Achondroplasia. Reply.,"Savarirayan Ravi, Rogoff Daniela",The New England journal of medicine,2025 09,10.1056/NEJMc2504219,,Correspondence
40532160,Oral Infigratinib Therapy in Children with Achondroplasia.,"Rico-Llanos Gustavo, Czyrek Aleksandra A, Krejci Pavel",The New England journal of medicine,2025 09,10.1056/NEJMc2504219,,Correspondence
40532159,Oral Infigratinib Therapy in Children with Achondroplasia.,Bittmann Stefan,The New England journal of medicine,2025 09,10.1056/NEJMc2504219,,Correspondence
40532158,Three Cases of Vertical Transmission of Clade Ib Mpox Virus.,"Vakaniaki Emmanuel Hasivirwe, Kuispond Nono-Raymond Swar, Hirata Yuichiro, Bangwen Eugene, Brosius Isabel",The New England journal of medicine,2025 09,10.1056/NEJMc2503347,,Correspondence
40532152,Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer.,"Srinivasan Ramaprasad, Gurram Sandeep, Singer Eric A, Sidana Abhinav, Al Harthy Munjid",The New England journal of medicine,2025 06,10.1056/NEJMoa2200900,"Hereditary leiomyomatosis and renal-cell cancer (HLRCC) is an inherited disorder characterized by germline pathogenic variants in the gene encoding fumarate hydratase and an increased risk of papillary renal-cell carcinoma. No effective therapy is known for patients with advanced HLRCC-associated papillary renal-cell carcinoma, and most patients die from progressive disease.",Correspondence
40521799,Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.,"Munir Talha, Girvan Sean, Cairns David A, Bloor Adrian, Allsup David",The New England journal of medicine,2025 09,10.1056/NEJMoa2504341,An interim analysis of progression-free survival in this trial showed that ibrutinib-venetoclax was superior to fludarabine-cyclophosphamide-rituximab (FCR) among patients with chronic lymphocytic leukemia (CLL). Whether ibrutinib-venetoclax is more effective than ibrutinib alone is unclear.,Original Article
40513032,Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin.,"Curtis David J, Patil Sushrut S, Reynolds John, Purtill Duncan, Lewis Clinton",The New England journal of medicine,2025 07,10.1056/NEJMoa2503189,Allogeneic peripheral-blood stem-cell transplantation (SCT) from a matched related donor after myeloablative conditioning is the preferred curative treatment for patients with high-risk blood cancers. The combination of a calcineurin inhibitor and an antimetabolite remains standard care for graft-versus-host disease (GVHD) prophylaxis in these patients. Data from two randomized trials have suggested that post-transplantation cyclophosphamide can reduce the risk of GVHD after SCT from a matched d...,Original Article
40513026,Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis.,"Maitland Kathryn, Ouattara San Maurice, Sainna Hadiza, Chara Abdullahi, Ogundipe Oluwakemi F",The New England journal of medicine,2025 10,10.1056/NEJMoa2505752,"International recommendations advise against the use of intravenous rehydration therapy in children with severe acute malnutrition because of the concern about fluid overload, but evidence to support this concern is lacking. Given the high mortality associated with the current recommendations, the adoption of intravenous rehydration strategies might improve outcomes.",Correspondence
40513024,Proportional-Assist Ventilation for Minimizing the Duration of Mechanical Ventilation.,"Bosma Karen J, Burns Karen E A, Martin Claudio M, Skrobik Yoanna, Mancebo Cort&#xe9;s Jordi",The New England journal of medicine,2025 09,10.1056/NEJMoa2505708,"In critically ill patients, acceleration of liberation from mechanical ventilation is important in order to reduce the risk of complications and to improve long-term outcomes. Whether the use of proportional-assist ventilation with load-adjustable gain factors (PAV+) results in a shorter time to successful liberation from mechanical ventilation than pressure-support ventilation (PSV) is unclear.",Original Article
40503714,A Crossover Trial of Hospital-Wide Lactated Ringer's Solution versus Normal Saline.,"McIntyre Lauralyn, Fergusson Dean, McArdle Tracy, English Shane, Cook Deborah J",The New England journal of medicine,2025 08,10.1056/NEJMoa2416761,Whether lactated Ringer's solution is clinically superior to normal saline for routine intravenous administration of fluids is uncertain.,Original Article
40503713,A Randomized Trial of Acute Normovolemic Hemodilution in Cardiac Surgery.,"Monaco Fabrizio, Lei Chong, Bonizzoni Matteo Aldo, Efremov Sergey, Morselli Federica",The New England journal of medicine,2025 07,10.1056/NEJMoa2504948,"Patients undergoing cardiac surgery often receive red-cell transfusions, along with the associated risks and costs. Early intraoperative normovolemic hemodilution (i.e., acute normovolemic hemodilution [ANH]) is a blood-conservation technique that entails autologous blood collection before initiation of cardiopulmonary bypass and reinfusion of the collected blood after bypass weaning. More data are needed on whether ANH reduces the number of patients receiving allogeneic red-cell transfusion.",Original Article
40499184,"Case 4-2025: A Man with Syncope, Ankle Swelling, and Abnormal Chest Imaging. Reply.","Restrepo Daniel, Sparks Jeffrey A",The New England journal of medicine,2025 09,10.1056/NEJMc2503283,,Correspondence
40499183,"Case 4-2025: A Man with Syncope, Ankle Swelling, and Abnormal Chest Imaging.","Lipsker Gabriel, Lipsker Dan",The New England journal of medicine,2025 09,10.1056/NEJMc2503283,,Correspondence
40499182,Blinatumomab in Childhood B-Cell Acute Lymphoblastic Leukemia. Reply.,"Gupta Sumit, Rau Rachel E, Loh Mignon L",The New England journal of medicine,2025 09,10.1056/NEJMc2504183,,Correspondence
40499181,Blinatumomab in Childhood B-Cell Acute Lymphoblastic Leukemia.,"Hodder Angus, Vora Ajay, Samarasinghe Sujith",The New England journal of medicine,2025 09,10.1056/NEJMc2504183,,Correspondence
40499180,Long-Term Effects of Empagliflozin in Chronic Kidney Disease. Reply.,"Herrington William G, Staplin Natalie, Haynes Richard",The New England journal of medicine,2025 09,10.1056/NEJMc2504181,,Correspondence
40499179,Long-Term Effects of Empagliflozin in Chronic Kidney Disease.,"Yoshimoto Norifumi, Azegami Tatsuhiko, Hayashi Kaori",The New England journal of medicine,2025 09,10.1056/NEJMc2504181,,Correspondence
40499178,Long-Term Effects of Empagliflozin in Chronic Kidney Disease.,Ilany Jacob,The New England journal of medicine,2025 09,10.1056/NEJMc2504181,,Correspondence
40499177,BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy.,"Zhang Lele, Gao Zhen, Pan Hong, Li Ruonan, Fang Liwei",The New England journal of medicine,2025 09,10.1056/NEJMc2502297,,Correspondence
40499172,Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B.,"Reiss Ulrike M, Davidoff Andrew M, Tuddenham Edward G D, Chowdary Pratima, McIntosh Jenny",The New England journal of medicine,2025 06,10.1056/NEJMoa2414783,Adeno-associated virus (AAV)-mediated gene therapy has emerged as a promising treatment for hemophilia B. Data on safety and durability from 13 years of follow-up in a cohort of patients who had been successfully treated with scAAV2/8-LP1-hFIXco gene therapy are now available.,Correspondence
40470996,Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.,"Agarwal Rajiv, Green Jennifer B, Heerspink Hiddo J L, Mann Johannes F E, McGill Janet B",The New England journal of medicine,2025 08,10.1056/NEJMoa2410659,"Limited evidence exists to support the simultaneous initiation of sodium-glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in persons with chronic kidney disease and type 2 diabetes.",Original Article
40466086,Case 2-2025: A Man with Loss of Consciousness and a Fall. Reply.,"Azar Sharl S, Shappell Eric F",The New England journal of medicine,2025 09,10.1056/NEJMc2503273,,Correspondence
40466085,Case 2-2025: A Man with Loss of Consciousness and a Fall.,"Zhou Yangzhong, Hu Shikai, Zhao Jiuliang",The New England journal of medicine,2025 09,10.1056/NEJMc2503273,,Correspondence
40466084,Oral Hairy Leukoplakia. Reply.,"Karakioulaki Meropi, Schauer Franziska",The New England journal of medicine,2025 09,10.1056/NEJMc2504743,,Correspondence
40466083,Oral Hairy Leukoplakia.,"Villa Alessandro, Lodolo Michele, Woo Sook Bin",The New England journal of medicine,2025 09,10.1056/NEJMc2504743,,Correspondence
40466082,Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. Reply.,"Brown Jennifer R, Miller Kara, Munugalavadla Veerendra",The New England journal of medicine,2025 09,10.1056/NEJMc2503839,,Correspondence
40466081,Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.,"Mohty Mohamad, Kharfan-Dabaja Mohamed A",The New England journal of medicine,2025 09,10.1056/NEJMc2503839,,Correspondence
40466080,TAVR for Asymptomatic Severe Aortic Stenosis. Reply.,Blankenberg Stefan,The New England journal of medicine,2025 09,10.1056/NEJMc2502177,,Correspondence
40466079,TAVR for Asymptomatic Severe Aortic Stenosis. Reply.,"G&#xe9;n&#xe9;reux Philippe, Schwartz Allan, Leon Martin B",The New England journal of medicine,2025 09,10.1056/NEJMc2502177,,Correspondence
40466078,TAVR for Asymptomatic Severe Aortic Stenosis.,"Barbanti Marco, Costa Giuliano",The New England journal of medicine,2025 09,10.1056/NEJMc2502177,,Correspondence
40466077,TAVR for Asymptomatic Severe Aortic Stenosis.,"Auer Johann, Ankersmit Hendrik J, Auer Lisa",The New England journal of medicine,2025 09,10.1056/NEJMc2502177,,Correspondence
40466076,TAVR for Asymptomatic Severe Aortic Stenosis.,"Toggweiler Stefan, Loretz Lucca, Henzen Christoph",The New England journal of medicine,2025 09,10.1056/NEJMc2502177,,Correspondence
40466075,TAVR for Asymptomatic Severe Aortic Stenosis.,"Hoffman Benjamin U, Ben-Yehuda Ori",The New England journal of medicine,2025 09,10.1056/NEJMc2502177,,Correspondence
40466074,TAVR for Asymptomatic Severe Aortic Stenosis.,"Natale Francesco, Golino Paolo, Cimmino Giovanni",The New England journal of medicine,2025 09,10.1056/NEJMc2502177,,Correspondence
40466073,Bedaquiline Activity against Leprosy.,"Fomba Abdoulaye, Haidara Fadima C, Kodio Mamoudou, Arama Catherine, Cambau Emmanuelle",The New England journal of medicine,2025 09,10.1056/NEJMc2412487,,Correspondence
40466066,A Trial of Trimethoprim-Sulfamethoxazole in Pregnancy to Improve Birth Outcomes.,"Chasekwa Bernard, Munhanzi Fortunate, Madhuyu Lenin, Mbewe Gabriel, Mabika Vincent",The New England journal of medicine,2025 06,10.1056/NEJMoa2408114,Maternal infections underlie several adverse birth outcomes. Whether trimethoprim-sulfamethoxazole prophylaxis during pregnancy will improve birth outcomes is unknown.,Original Article
40466065,Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.,"Mamounas Eleftherios P, Bandos Hanna, White Julia R, Julian Thomas B, Khan Atif J",The New England journal of medicine,2025 06,10.1056/NEJMoa2414859,"The benefit of regional nodal irradiation in the treatment of breast cancer is well established for patients with pathologically positive axillary nodes, but whether it is also beneficial for patients whose nodes become pathologically tumor free (ypN0) after neoadjuvant chemotherapy remains unclear.",Correspondence
40466062,Corynebacterium diphtheriae Outbreak in Migrant Populations in Europe.,"Hoefer Andreas, Seth-Smith Helena, Palma Federica, Schindler Stefanie, Freschi Luca",The New England journal of medicine,2025 06,10.1056/NEJMoa2311981,"A surge of cases of Corynebacterium diphtheriae infection was observed in reception centers for migrants in Europe beginning in the summer of 2022. Most of the cases were cutaneous, although some respiratory cases as well as one death were reported. A pan-European consortium was created to assess the clinical, epidemiologic, and microbiologic features of this outbreak.",Original Article
40459097,Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma.,"Perrot Aurore, Lambert J&#xe9;r&#xf4;me, Hulin Cyrille, Pieragostini Andrea, Karlin Lionel",The New England journal of medicine,2025 07,10.1056/NEJMoa2505133,Measurable residual disease (MRD) is a major prognostic factor in newly diagnosed multiple myeloma. An assessment of an MRD-guided consolidation strategy in patients who are eligible for autologous stem-cell transplantation (ASCT) may be useful.,Original Article
40454646,Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.,"Mountzios Giannis, Sun Longhua, Cho Byoung Chul, Demirci Umut, Baka Sofia",The New England journal of medicine,2025 07,10.1056/NEJMoa2502099,"Tarlatamab, a bispecific delta-like ligand 3-directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer. Whether tarlatamab is more effective than chemotherapy in the treatment of patients whose small-cell lung cancer has progressed during or after initial platinum-based chemotherapy is not known.",Original Article
40454645,"Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer.","Campone Mario, De Laurentiis Michelino, Jhaveri Komal, Hu Xichun, Ladoire Sylvain",The New England journal of medicine,2025 08,10.1056/NEJMoa2505725,Vepdegestrant is an oral proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader that directly harnesses the ubiquitin-proteasome system.,Original Article
40454643,Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.,"Janjigian Yelena Y, Al-Batran Salah-Eddin, Wainberg Zev A, Muro Kei, Molena Daniela",The New England journal of medicine,2025 07,10.1056/NEJMoa2503701,"Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas, but recurrence rates remain high. Immunotherapy plus chemotherapy may improve outcomes.",Correspondence
40454642,Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.,"Forde Patrick M, Spicer Jonathan D, Provencio Mariano, Mitsudomi Tetsuya, Awad Mark M",The New England journal of medicine,2025 08,10.1056/NEJMoa2502931,Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non-small-cell lung cancer (NSCLC) in a phase 3 trial. Data are needed on overall survival.,Correspondence
40454641,Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.,"Jhaveri Komal L, Im Seock-Ah, Saura Cristina, Loibl Sibylle, Kalinsky Kevin",The New England journal of medicine,2025 07,10.1056/NEJMoa2501796,"In the phase 3, double-blind, randomized INAVO120 trial, treatment with inavolisib plus palbociclib-fulvestrant led to a significant progression-free survival benefit, as compared with placebo plus palbociclib-fulvestrant, among patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who had had relapse during or within 12 months after completion of adjuvant endocrine therapy.",Correspondence
40454639,Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma.,"Rischin Danny, Porceddu Sandro, Day Fiona, Brungs Daniel P, Christie Hayden",The New England journal of medicine,2025 08,10.1056/NEJMoa2502449,Patients who have cutaneous squamous-cell carcinoma with high-risk features are at risk for recurrence after definitive local therapy. The benefit of systemic adjuvant therapy options has not been well established in clinical trials.,Original Article
40454637,First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.,"Bidard Fran&#xe7;ois-Cl&#xe9;ment, Mayer Erica L, Park Yeon Hee, Janni Wolfgang, Ma Cynthia",The New England journal of medicine,2025 08,10.1056/NEJMoa2502929,"Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor for advanced breast cancer. Camizestrant, a next-generation selective estrogen-receptor (ER) degrader and complete ER antagonist, has shown antitumor activity in ER-positive advanced breast cancer.",Original Article
40454634,Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer.,"Cardoso Fatima, Parke Susanne, Brennan Donal J, Briggs Paula, Donders Gilbert",The New England journal of medicine,2025 08,10.1056/NEJMoa2415566,"Women receiving endocrine therapy for hormone receptor (HR)-positive breast cancer or its prevention among those at high risk for breast cancer commonly have vasomotor symptoms. Data are lacking on the effects of elinzanetant, a neurokinin-targeted therapy shown to be effective in treating vasomotor symptoms, in this population.",Original Article
40454632,Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer.,"Shitara Kohei, Van Cutsem Eric, G&#xfc;m&#xfc;&#x15f; Mahmut, Lonardi Sara, de la Fouchardi&#xe8;re Christelle",The New England journal of medicine,2025 07,10.1056/NEJMoa2503119,"On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric cancer or gastroesophageal junction adenocarcinoma who had previously received trastuzumab-based therapy. Ramucirumab plus paclitaxel is also a standard second-line treatment option regardless of HER2 status.",Correspondence
40450658,Structured Exercise after Adjuvant Chemotherapy for Colon Cancer.,"Courneya Kerry S, Vardy Janette L, O'Callaghan Christopher J, Gill Sharlene, Friedenreich Christine M",The New England journal of medicine,2025 07,10.1056/NEJMoa2502760,"Preclinical and observational studies suggest that exercise may improve cancer outcomes. However, definitive level 1 evidence is lacking.",Original Article
40444708,"Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.","Elez Elena, Yoshino Takayuki, Shen Lin, Lonardi Sara, Van Cutsem Eric",The New England journal of medicine,2025 06,10.1056/NEJMoa2501912,"First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E-mutated metastatic colorectal cancer, an aggressive subtype with a poor prognosis, was compared with standard care (chemotherapy with or without bevacizumab) in an open-label, phase 3 trial, which showed significance regarding one of the two primary end points, objective response according to blinded independent central review (odds ratio fo...",Correspondence
40435488,Identification and Treatment of Alcohol Use Disorder. Reply.,Haber Paul S,The New England journal of medicine,2025 05,10.1056/NEJMc2502755,,Correspondence
40435487,Identification and Treatment of Alcohol Use Disorder.,"Bowdring Molly A, Mendelson John, Prochaska Judith J",The New England journal of medicine,2025 09,10.1056/NEJMc2502755,,Correspondence
40435486,Identification and Treatment of Alcohol Use Disorder.,"Braillon Alain, Naudet Florian",The New England journal of medicine,2025 05,10.1056/NEJMc2502755,,Correspondence
40435485,Identification and Treatment of Alcohol Use Disorder.,"Blaney Hanna, Tapper Elliot",The New England journal of medicine,2025 05,10.1056/NEJMc2502755,,Correspondence
40435484,Remibrutinib in Chronic Spontaneous Urticaria. Reply.,"Metz Martin, Haemmerle Sibylle",The New England journal of medicine,2025 05,10.1056/NEJMc2504726,,Correspondence
40435483,Remibrutinib in Chronic Spontaneous Urticaria.,"Babaei Nickoulet, Yang Seanna, Wu Jashin J",The New England journal of medicine,2025 05,10.1056/NEJMc2504726,,Correspondence
40435482,Remibrutinib in Chronic Spontaneous Urticaria.,"Pousada-Fonseca &#xc1;lvaro, Pedreira-Bouzas Jorge",The New England journal of medicine,2025 05,10.1056/NEJMc2504726,,Correspondence
40435481,Remibrutinib in Chronic Spontaneous Urticaria.,"Jilma Bernd, Weiss-Tessbach Matthias",The New England journal of medicine,2025 05,10.1056/NEJMc2504726,,Correspondence
40435480,Colchicine and Spironolactone in Acute Myocardial Infarction. Reply.,"Jolly Sanjit S, d'Entremont Marc-Andr&#xe9;, Mian Rajibul",The New England journal of medicine,2025 05,10.1056/NEJMc2503896,,Correspondence
40435479,Colchicine and Spironolactone in Acute Myocardial Infarction. Reply.,"Jolly Sanjit S, d'Entremont Marc-Andr&#xe9;, Lee Shun Fu",The New England journal of medicine,2025 05,10.1056/NEJMc2503896,,Correspondence
40435478,Colchicine and Spironolactone in Acute Myocardial Infarction.,"Golino Michele, Van Tassell Benjamin, Abbate Antonio",The New England journal of medicine,2025 05,10.1056/NEJMc2503896,,Correspondence
40435477,Colchicine and Spironolactone in Acute Myocardial Infarction.,Kida Yujiro,The New England journal of medicine,2025 05,10.1056/NEJMc2503896,,Correspondence
40435476,Colchicine and Spironolactone in Acute Myocardial Infarction.,"Gu Hong-Qiu, Jiang Yong, Li Hao",The New England journal of medicine,2025 05,10.1056/NEJMc2503896,,Correspondence
40435475,Colchicine and Spironolactone in Acute Myocardial Infarction.,"van Twist Daan J L, Appelboom Yael",The New England journal of medicine,2025 05,10.1056/NEJMc2503896,,Correspondence
40435474,Colchicine and Spironolactone in Acute Myocardial Infarction.,Striessnig J&#xf6;rg,The New England journal of medicine,2025 05,10.1056/NEJMc2503896,,Correspondence
40435473,Daratumumab in Relapsed or Refractory Pediatric Immune Thrombocytopenia.,"Sun Ting, Chen Yunfei, Zhang Lei",The New England journal of medicine,2025 05,10.1056/NEJMc2501527,,Correspondence
40421736,Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.,"Ji Linong, Jiang Hongwei, Bi Yan, Li Hua, Tian Junhang",The New England journal of medicine,2025 06,10.1056/NEJMoa2411528,"Evidence suggests that incretin-based dual agonist pharmacotherapy is helpful in persons with obesity. Mazdutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, may have efficacy in persons with overweight or obesity.",Correspondence
40396577,Intravenous Tenecteplase before Thrombectomy in Stroke.,"Qiu Zhongming, Li Fengli, Sang Hongfei, Yuan Guangxiong, Xie Dongjing",The New England journal of medicine,2025 07,10.1056/NEJMoa2503867,The safety and efficacy of treatment with intravenous tenecteplase before endovascular thrombectomy in patients with acute ischemic stroke due to large-vessel occlusion remain uncertain.,Original Article
40388330,As-Needed Albuterol-Budesonide in Mild Asthma.,"LaForce Craig, Albers Frank, Danilewicz Anna, Jeynes-Ellis Allison, Kraft Monica",The New England journal of medicine,2025 07,10.1056/NEJMoa2504544,As-needed use of albuterol-budesonide has been shown to result in a significantly lower risk of severe asthma exacerbation than as-needed use of albuterol alone among patients with moderate-to-severe asthma. Data on albuterol-budesonide in mild asthma are needed.,Original Article
40388329,Nerandomilast in Patients with Progressive Pulmonary Fibrosis.,"Maher Toby M, Assassi Shervin, Azuma Arata, Cottin Vincent, Hoffmann-Vold Anna-Maria",The New England journal of medicine,2025 06,10.1056/NEJMoa2503643,"Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory properties. Nerandomilast has been shown to slow the progression of idiopathic pulmonary fibrosis, but an assessment of its effects in other types of progressive pulmonary fibrosis is needed.",Correspondence
40387033,Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis.,"Richeldi Luca, Azuma Arata, Cottin Vincent, Kreuter Michael, Maher Toby M",The New England journal of medicine,2025 06,10.1056/NEJMoa2414108,"Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory effects. In a phase 2 trial involving patients with idiopathic pulmonary fibrosis, treatment with nerandomilast stabilized lung function over a period of 12 weeks.",Correspondence
40387025,Navigational Bronchoscopy or Transthoracic Needle Biopsy for Lung Nodules.,"Lentz Robert J, Frederick-Dyer Katherine, Planz Virginia B, Koyama Tatsuki, Aboudara Matthew C",The New England journal of medicine,2025 06,10.1056/NEJMoa2414059,"Each year, millions of pulmonary nodules are identified incidentally or through lung cancer screening, and many involve biopsy to distinguish cancer from benign processes. Both navigational bronchoscopy and computed tomography-guided transthoracic needle biopsy are commonly used in patients undergoing biopsies of peripheral pulmonary nodules, but the relative diagnostic accuracy of these two approaches is unclear.",Original Article
40387020,First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate.,"Kahlmann Vivienne, Janssen Bon&#xe1;s Montse, Moor Catharina C, Grutters Jan C, Mostard R&#xe9;my L M",The New England journal of medicine,2025 07,10.1056/NEJMoa2501443,"Prednisone is currently recommended as the first-line treatment for pulmonary sarcoidosis but is associated with many side effects. Methotrexate, which is recommended as a second-line treatment, appears to have fewer side effects than prednisone but a slower onset of action. Data are needed on the efficacy and side-effect profile of methotrexate as compared with prednisone as first-line treatment for pulmonary sarcoidosis.",Original Article
40373211,Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease.,"Musunuru Kiran, Grandinette Sarah A, Wang Xiao, Hudson Taylor R, Briseno Kevin",The New England journal of medicine,2025 06,10.1056/NEJMoa2504747,"Base editors can correct disease-causing genetic variants. After a neonate had received a diagnosis of severe carbamoyl-phosphate synthetase 1 deficiency, a disease with an estimated 50% mortality in early infancy, we immediately began to develop a customized lipid nanoparticle-delivered base-editing therapy. After regulatory approval had been obtained for the therapy, the patient received two infusions at approximately 7 and 8 months of age. In the 7 weeks after the initial infusion, the patien...",Original Article
40367387,"Alternative Complement Pathway, Iptacopan, and IgA Nephropathy. Reply.","Barratt Jonathan, Perkovic Vlado, Rizk Dana V",The New England journal of medicine,2025 05,10.1056/NEJMc2503117,,Correspondence
40367386,"Alternative Complement Pathway, Iptacopan, and IgA Nephropathy.","Angeletti Andrea, Marasa Maddalena, Cravedi Paolo",The New England journal of medicine,2025 05,10.1056/NEJMc2503117,,Correspondence
40367385,"Alternative Complement Pathway, Iptacopan, and IgA Nephropathy.","Poppelaars Felix, Faria Bernardo, Thurman Joshua M",The New England journal of medicine,2025 05,10.1056/NEJMc2503117,,Correspondence
40367384,Longitudinal Changes in Airway Mucus Plugs and FEV1 in COPD.,"Mettler Sofia K, Nardelli Pietro, Campo Monica Iturrioz, San Jos&#xe9; Est&#xe9;par Rub&#xe9;n, Manapragada Padma P",The New England journal of medicine,2025 09,10.1056/NEJMc2502456,,Correspondence
40367375,Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.,"Musiime Victor, Bwakura-Dangarembizi Mutsa, Szubert Alexander J, Mumbiro Vivian, Mujuru Hilda A",The New England journal of medicine,2025 05,10.1056/NEJMoa2404597,Children living with human immunodeficiency virus (HIV) have limited options for second-line antiretroviral therapy (ART).,Original Article
40367374,"Oveporexton, an Oral Orexin Receptor 2-Selective Agonist, in Narcolepsy Type 1.","Dauvilliers Yves, Plazzi Giuseppe, Mignot Emmanuel, Lammers Gert Jan, Del R&#xed;o Villegas Rafael",The New England journal of medicine,2025 05,10.1056/NEJMoa2405847,"Narcolepsy type 1 is a disorder of hypersomnolence caused by a loss of orexin neurons, which results in low orexin levels in the brain.",Original Article
40367373,Loss of Subsidized Drug Coverage and Mortality among Medicare Beneficiaries.,"Roberts Eric T, Phelan Jessica, Schwartz Aaron L, Meara Ellen, Ruggiero Dominic",The New England journal of medicine,2025 05,10.1056/NEJMsa2414435,"A total of 14 million Medicare beneficiaries receive the Low-Income Subsidy (LIS), which reduces cost sharing in Medicare Part D. Losing the LIS may impede medication access and affect mortality.",Correspondence
40353578,Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.,"Aronne Louis J, Horn Deborah Bade, le Roux Carel W, Ho Wayne, Falcon Beverly L",The New England journal of medicine,2025 07,10.1056/NEJMoa2416394,Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown.,Original Article
40341827,Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.,"Noureddin Mazen, Rinella Mary E, Chalasani Naga P, Neff Guy W, Lucas K Jean",The New England journal of medicine,2025 06,10.1056/NEJMoa2502242,"In phase 2 trials involving patients with stage 2 or 3 fibrosis caused by metabolic dysfunction-associated steatohepatitis (MASH), efruxifermin, a bivalent fibroblast growth factor 21 (FGF21) analogue, reduced fibrosis and resolved MASH. Data are needed on the efficacy and safety of efruxifermin in patients with compensated cirrhosis (stage 4 fibrosis) caused by MASH.",Original Article
40337982,Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.,"Nicholls Stephen J, Nelson Adam J, Ditmarsch Marc, Kastelein John J P, Ballantyne Christie M",The New England journal of medicine,2025 07,10.1056/NEJMoa2415820,Obicetrapib is a highly selective cholesteryl ester transfer protein inhibitor that reduces low-density lipoprotein (LDL) cholesterol levels. The efficacy and safety of obicetrapib have not been fully characterized among patients at high risk for cardiovascular events.,Original Article
40334174,More on Acquired Osteomalacia and Autoantibodies against PHEX. Reply.,"Hoshino Yoshitomo, Okamoto Kazuo, Ito Nobuaki",The New England journal of medicine,2025 05,10.1056/NEJMc2502747,,Correspondence
40334173,More on Acquired Osteomalacia and Autoantibodies against PHEX.,"Minisola Salvatore, Pepe Jessica, Cipriani Cristiana",The New England journal of medicine,2025 05,10.1056/NEJMc2502747,,Correspondence
40334172,Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. Reply.,"Fontana Marianna, Witteles Ronald M, Eraly Satish A",The New England journal of medicine,2025 05,10.1056/NEJMc2501792,,Correspondence
40334171,Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.,Zaidan Mohamad,The New England journal of medicine,2025 05,10.1056/NEJMc2501792,,Correspondence
40334170,Cabozantinib in Advanced Neuroendocrine Tumors. Reply.,"Chan Jennifer A, Geyer Susan, Meyerhardt Jeffrey A",The New England journal of medicine,2025 05,10.1056/NEJMc2503524,,Correspondence
40334169,Cabozantinib in Advanced Neuroendocrine Tumors.,Tsilimigras Diamantis I,The New England journal of medicine,2025 05,10.1056/NEJMc2503524,,Correspondence
40334168,Liraglutide for Children 6 to <12 Years of Age with Obesity. Reply.,"Fox Claudia K, Harder-Lauridsen Nina M, Arslanian Silva",The New England journal of medicine,2025 05,10.1056/NEJMc2503084,,Correspondence
40334167,Liraglutide for Children 6 to <12 Years of Age with Obesity.,"Egan Josephine M, Kapogiannis Dimitrios",The New England journal of medicine,2025 05,10.1056/NEJMc2503084,,Correspondence
40334166,Liraglutide for Children 6 to <12 Years of Age with Obesity.,"Ji Conghua, Wang Minyan",The New England journal of medicine,2025 05,10.1056/NEJMc2503084,,Correspondence
40334165,Liraglutide for Children 6 to <12 Years of Age with Obesity.,Malozowski Saul,The New England journal of medicine,2025 05,10.1056/NEJMc2503084,,Correspondence
40334164,Pegivirus-Associated Encephalomyelitis in Immunosuppressed Patients.,"Scheibe Franziska, Melchert Julia, Radbruch Helena, Siebert Eberhard, Best Till D",The New England journal of medicine,2025 05,10.1056/NEJMc2501512,,Correspondence
40334157,Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure.,"Svoboda Jakub, Landsburg Daniel J, Gerson James, Nasta Sunita D, Barta Stefan K",The New England journal of medicine,2025 05,10.1056/NEJMoa2408771,"Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armored) CAR T-cell product (huCART19-IL18) that secretes interleukin-18 to enhance antitumor activity.",Correspondence
40334156,BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection.,"Schmidt Alexander C, Fairlie Lee, Hellstr&#xf6;m Elizabeth, Luabeya Kany Kany Angelique, Middelkoop Keren",The New England journal of medicine,2025 05,10.1056/NEJMoa2412381,"In a previous phase 2 trial, bacille Calmette-Gu&#xe9;rin (BCG) revaccination was not shown to provide protection from primary Mycobacterium tuberculosis infection but prevented sustained M. tuberculosis infection, defined by an initial conversion on a QuantiFERON-TB (QFT) test (an interferon-&#x3b3; release assay) from negative to positive, followed by two additional positive QFT tests at 3 and 6 months after the initial conversion (a secondary end point). A vaccine efficacy of 45% (95% confide...",Original Article
40305733,The Physiology of Hunger. Reply.,Fasano Alessio,The New England journal of medicine,2025 04,10.1056/NEJMc2502445,,Correspondence
40305732,The Physiology of Hunger.,"Lund Jens, S&#xf8;rensen Thorkild I A, Friedman Mark I",The New England journal of medicine,2025 05,10.1056/NEJMc2502445,,Correspondence
40305731,The Physiology of Hunger.,"Loss Sergio, Stefani Joel, Viana Luciana",The New England journal of medicine,2025 05,10.1056/NEJMc2502445,,Correspondence
40305730,The Physiology of Hunger.,"Rahmoune Hakim, Boutrid Nada",The New England journal of medicine,2025 04,10.1056/NEJMc2502445,,Correspondence
40305729,Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A. Reply.,"Srivastava Alok, Spencer Trent",The New England journal of medicine,2025 04,10.1056/NEJMc2502741,,Correspondence
40305728,Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A.,Zhang Kaili,The New England journal of medicine,2025 05,10.1056/NEJMc2502741,,Correspondence
40305727,Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A.,"Sanal Madhusudana Girija, Jindal Ankur",The New England journal of medicine,2025 05,10.1056/NEJMc2502741,,Correspondence
40305726,Initial Intraosseous or Intravenous Access for Out-of-Hospital Cardiac Arrest. Reply.,"Vallentin Mikael F, Granfeldt Asger, Andersen Lars W",The New England journal of medicine,2025 04,10.1056/NEJMc2502751,,Correspondence
40305725,Initial Intraosseous or Intravenous Access for Out-of-Hospital Cardiac Arrest. Reply.,"Couper Keith, Fothergill Rachael T, Perkins Gavin D",The New England journal of medicine,2025 04,10.1056/NEJMc2502751,,Correspondence
40305724,Initial Intraosseous or Intravenous Access for Out-of-Hospital Cardiac Arrest.,"van Schuppen Hans, Schober Patrick",The New England journal of medicine,2025 05,10.1056/NEJMc2502751,,Correspondence
40305723,Initial Intraosseous or Intravenous Access for Out-of-Hospital Cardiac Arrest.,"Lupton Joshua R, Jui Jonathan, Daya Mohamad R",The New England journal of medicine,2025 05,10.1056/NEJMc2502751,,Correspondence
40305722,Glofitamab with Polatuzumab Vedotin in Refractory Burkitt's Lymphoma.,"Prica Anca, Roschewski Mark, Beale Peter, Pittaluga Stefania, Delabie Jan",The New England journal of medicine,2025 04,10.1056/NEJMc2501018,,Correspondence
40305712,Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype.,"Sciurba Frank C, Criner Gerard J, Christenson Stephanie A, Martinez Fernando J, Papi Alberto",The New England journal of medicine,2025 05,10.1056/NEJMoa2413181,"Mepolizumab is a humanized monoclonal antibody that targets interleukin-5, a cytokine that plays a central role in eosinophilic inflammation, which is present in 20 to 40% of patients with chronic obstructive pulmonary disease (COPD).",Original Article
40305711,Lentiviral Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1.,"Booth Claire, Sevilla Juli&#xe1;n, Almarza Elena, Kuo Caroline Y, Zubicaray Josune",The New England journal of medicine,2025 05,10.1056/NEJMoa2407376,"The &#x3b2;2 common integrin subunit CD18 is essential for leukocyte-endothelial adhesion and extravasation to inflamed or infected tissue. Damaging variants in ITGB2, which encodes CD18, cause leukocyte adhesion deficiency type I (LAD-I), an inborn error of immunity that leads to frequent life-threatening infections and a high risk of death among affected children. Allogeneic hematopoietic stem-cell transplantation (HSCT) represents a curative treatment but is limited by donor availability, a h...",Original Article
40305710,Identification of Hepatic-like EPO as a Cause of Polycythemia.,"Martin Laurent, Maric Darko, Idriss Salam, Delamare Marine, Le Roy Amandine",The New England journal of medicine,2025 05,10.1056/NEJMoa2414954,"Secondary erythrocytosis often results from conditions that cause tissue hypoxia or an improper increase in erythropoietin (EPO) production. EPO, the major regulator of erythropoiesis, has a complex and tightly regulated expression during development, with a liver-to-kidney switch shortly after birth.",Original Article
40305708,Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.,"Sanyal Arun J, Newsome Philip N, Kliers Iris, &#xd8;stergaard Laura Harms, Long Michelle T",The New England journal of medicine,2025 06,10.1056/NEJMoa2413258,"Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).",Original Article
40293180,Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer.,"Heymach John V, Ruiter Gerrina, Ahn Myung-Ju, Girard Nicolas, Smit Egbert F",The New England journal of medicine,2025 06,10.1056/NEJMoa2503704,"Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)-mutant non-small-cell lung cancer (NSCLC). Zongertinib is an oral, irreversible, HER2-selective tyrosine kinase inhibitor that has been shown to have efficacy in persons with advanced or metastatic solid tumors with HER2 alterations in a phase 1 study.",Correspondence
40293177,Nonoperative Management of Mismatch Repair-Deficient Tumors.,"Cercek Andrea, Foote Michael B, Rousseau Benoit, Smith J Joshua, Shia Jinru",The New England journal of medicine,2025 06,10.1056/NEJMoa2404512,"Among patients with mismatch repair-deficient (dMMR), locally advanced rectal cancer, neoadjuvant checkpoint blockade eliminated the need for surgery in a high proportion of patients. Whether this approach can be extended to all early-stage dMMR solid tumors, regardless of tumor site, is unknown.",Correspondence
40267445,APOL1 Bi- and Monoallelic Variants and Chronic Kidney Disease in West Africans. Reply.,"Gbadegesin Rasheed A, Adu Dwomoa, Ojo Akinlolu",The New England journal of medicine,2025 04,10.1056/NEJMc2502038,,Correspondence
40267444,APOL1 Bi- and Monoallelic Variants and Chronic Kidney Disease in West Africans.,Ingwiller Maxime,The New England journal of medicine,2025 04,10.1056/NEJMc2502038,,Correspondence
40267443,APOL1 Bi- and Monoallelic Variants and Chronic Kidney Disease in West Africans.,Zhou Xu-Jie,The New England journal of medicine,2025 04,10.1056/NEJMc2502038,,Correspondence
40267442,Oral Anticoagulation during TAVI. Reply.,"van Ginkel Dirk Jan, Bor Willem L, Ten Berg Jurri&#xeb;n M",The New England journal of medicine,2025 04,10.1056/NEJMc2502740,,Correspondence
40267441,Oral Anticoagulation during TAVI.,"Hudzik Bartosz, Skulik Przemys&#x142;aw, G&#x105;sior Mariusz",The New England journal of medicine,2025 04,10.1056/NEJMc2502740,,Correspondence
40267440,Tirzepatide for Heart Failure and Obesity. Reply.,"Packer Milton, Kramer Christopher M, Borlaug Barry A",The New England journal of medicine,2025 04,10.1056/NEJMc2502743,,Correspondence
40267439,Tirzepatide for Heart Failure and Obesity.,Ali M Kasim,The New England journal of medicine,2025 04,10.1056/NEJMc2502743,,Correspondence
40267438,Tirzepatide for Heart Failure and Obesity.,"Marine Joseph E, Mandrola John, Prasad Vinay",The New England journal of medicine,2025 04,10.1056/NEJMc2502743,,Correspondence
40267437,Tirzepatide for Heart Failure and Obesity.,"Krakauer Jesse C, Krakauer Nir Y",The New England journal of medicine,2025 04,10.1056/NEJMc2502743,,Correspondence
40267436,Tirzepatide for Heart Failure and Obesity.,Wagner Jeffrey,The New England journal of medicine,2025 04,10.1056/NEJMc2502743,,Correspondence
40267435,Performance of Dialysis Facilities after Health-Equity Scoring Incentive.,"Koukounas Kalli G, Dixit Meehir N, Thorsness Rebecca, Patzer Rachel E, Wilk Adam S",The New England journal of medicine,2025 09,10.1056/NEJMc2413208,,Correspondence
40267426,Long-Term Effects of Atidarsagene Autotemcel for Metachromatic Leukodystrophy.,"Fumagalli Francesca, Calbi Valeria, Gallo Vera, Zambon Alberto Andrea, Recupero Salvatore",The New England journal of medicine,2025 04,10.1056/NEJMoa2405727,"Metachromatic leukodystrophy (MLD) is an ultrarare, severe lysosomal storage disorder caused by a deficiency of arylsulfatase A (ARSA).",Original Article
40267425,Tumor-Infiltrating Clonal Hematopoiesis.,"Pich Oriol, Bernard Elsa, Zagorulya Maria, Rowan Andrew, Pospori Constandina",The New England journal of medicine,2025 04,10.1056/NEJMoa2413361,"Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition associated with increased mortality among patients with cancer. CHIP mutations with high variant-allele frequencies can be detected in tumors, a phenomenon we term tumor-infiltrating clonal hematopoiesis (TI-CH). The frequency of TI-CH and its effect on tumor evolution are unclear.",Original Article
40267424,Efficacy of Baloxavir Treatment in Preventing Transmission of Influenza.,"Monto Arnold S, Kuhlbusch Klaus, Bernasconi Corrado, Cao Bin, Cohen Herman Avner",The New England journal of medicine,2025 04,10.1056/NEJMoa2413156,"Baloxavir marboxil (baloxavir) rapidly reduces influenza virus shedding, which suggests that it may reduce transmission. Studies of treatment with neuraminidase inhibitors have not shown sufficient evidence that they prevent transmission to contacts.",Original Article
40267423,Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.,"Chalmers James D, Burgel Pierre-R&#xe9;gis, Daley Charles L, De Soyza Anthony, Haworth Charles S",The New England journal of medicine,2025 04,10.1056/NEJMoa2411664,"In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP-1), targets neutrophil serine proteases, key mediators of neutrophilic inflammation.",Correspondence
40267417,Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension.,"Laffin Luke J, Kopjar Branko, Melgaard Carrie, Wolski Kathy, Ibbitson Jessica",The New England journal of medicine,2025 05,10.1056/NEJMoa2501440,"Aldosterone dysregulation contributes to hypertension. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited.",Correspondence
40239087,Hemophagocytic Lymphohistiocytosis. Reply.,Henter Jan-Inge,The New England journal of medicine,2025 04,10.1056/NEJMc2503087,,Correspondence
40239086,Hemophagocytic Lymphohistiocytosis.,Hoover Jon,The New England journal of medicine,2025 04,10.1056/NEJMc2503087,,Correspondence
40239085,Hemophagocytic Lymphohistiocytosis.,Hagar R Ward,The New England journal of medicine,2025 04,10.1056/NEJMc2503087,,Correspondence
40239084,Hemophagocytic Lymphohistiocytosis.,"Chen Luke Y C, Goubran Mariam, Spaner Caroline",The New England journal of medicine,2025 04,10.1056/NEJMc2503087,,Correspondence
40239083,Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation. Reply.,"Ruff Christian T, Goodrich Erica L, Sabatine Marc S",The New England journal of medicine,2025 05,10.1056/NEJMc2502454,,Correspondence
40239082,Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.,"Raschi Emanuel, Squizzato Alessandro",The New England journal of medicine,2025 05,10.1056/NEJMc2502454,,Correspondence
40239081,Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.,Henry Christopher,The New England journal of medicine,2025 05,10.1056/NEJMc2502454,,Correspondence
40239080,Fracture Prevention with Infrequent Zoledronate in Women. Reply.,"Bolland Mark J, Reid Ian R, Grey Andrew",The New England journal of medicine,2025 05,10.1056/NEJMc2502046,,Correspondence
40239079,Fracture Prevention with Infrequent Zoledronate in Women.,Sheth Param Darpan,The New England journal of medicine,2025 05,10.1056/NEJMc2502046,,Correspondence
40239078,Fracture Prevention with Infrequent Zoledronate in Women.,Kornelius Edy,The New England journal of medicine,2025 05,10.1056/NEJMc2502046,,Correspondence
40239077,Perioperative Chemotherapy in Esophageal Cancer. Reply.,"Hoeppner Jens, Schmoor Claudia, Lordick Florian",The New England journal of medicine,2025 05,10.1056/NEJMc2502283,,Correspondence
40239076,Perioperative Chemotherapy in Esophageal Cancer.,"Qin Jie, Feng Bei, Huang Juanjuan",The New England journal of medicine,2025 05,10.1056/NEJMc2502283,,Correspondence
40239075,Disseminated Syphilis Caused by Two Recombining Treponema pallidum Strains.,"Lieberman Nicole A P, Mohamed Bakhash Shah A K, Nunley B Ethan, Li Muyi, Mau Brian",The New England journal of medicine,2025 04,10.1056/NEJMc2500231,,Correspondence
40239068,Fidanacogene Elaparvovec for Hemophilia B - A Multiyear Follow-up Study.,"Rasko John E J, Samelson-Jones Benjamin J, George Lindsey A, Giermasz Adam, Ducore Jonathan M",The New England journal of medicine,2025 04,10.1056/NEJMoa2307159,"Treatment with fidanacogene elaparvovec, a recombinant adeno-associated virus (AAV) vector developed for the treatment of hemophilia B, led to sustained expression of the high-activity factor IX variant (FIX-R338L, or FIX-Padua) in a phase 1-2a study. The long-term safety and efficacy of this treatment are not known.",Original Article
40239067,Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo.,"Ali Rosine, Alonga Jules, Biampata Jean-Luc, Kombozi Basika Michael, Maljkovic Berry Irina",The New England journal of medicine,2025 04,10.1056/NEJMoa2412439,"Tecovirimat is available for the treatment of mpox (formerly known as monkeypox) in Europe and the United States, on the basis of findings from efficacy studies in animals and safety evaluations in healthy humans. Evidence from randomized, controlled trials of safety and efficacy in patients with mpox is lacking.",Original Article
40214047,Challenges to the Future of a Robust Physician Workforce. Reply.,"Walensky Rochelle P, McCann Nicole C",The New England journal of medicine,2025 04,10.1056/NEJMc2502032,,Correspondence
